Infective endocarditis
- Overview
- Theory
- Diagnosis
- Management
- Follow up
- Resources
Treatment algorithm
Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups: see disclaimer
Look out for this icon: for treatment options that are affected, or added, as a result of your patient's comorbidities.
suspected infective endocarditis
supportive care
Use an airway, breathing, and circulation (ABC) approach to guide initial management.
Monitor controlled oxygen therapy. An upper SpO 2 limit of 96% is reasonable when administering supplemental oxygen to most patients with acute illness who are not at risk of hypercapnia.
Evidence suggests that liberal use of supplemental oxygen (target SpO 2 >96%) in acutely ill adults is associated with higher mortality than more conservative oxygen therapy.[53]Chu DK, Kim LH, Young PJ, et al. Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy (IOTA): a systematic review and meta-analysis. Lancet. 2018 Apr 28;391(10131):1693-705. http://www.ncbi.nlm.nih.gov/pubmed/29726345?tool=bestpractice.com
A lower target SpO 2 of 88% to 92% is appropriate if the patient is at risk of hypercapnic respiratory failure.[54]O'Driscoll BR, Howard LS, Earis J, et al. BTS guideline for oxygen use in adults in healthcare and emergency settings. Thorax. 2017 Jun;72(suppl 1):ii1-90. https://thorax.bmj.com/content/72/Suppl_1/ii1.long http://www.ncbi.nlm.nih.gov/pubmed/28507176?tool=bestpractice.com
If the patient requires fluid resuscitation, evidence from critically ill patients in general (not specifically just people with infective endocarditis) suggests that there is no difference in benefit between normal saline and a balanced crystalloid (such as Hartmann's solution [also known as Ringer's lactate] or Plasma-Lyte®), and therefore either choice of fluid is reasonable.[63]Zampieri FG, Machado FR, Biondi RS, et al. Effect of intravenous fluid treatment with a balanced solution vs 0.9% saline solution on mortality in critically ill patients: the BaSICS randomized clinical trial. JAMA. 2021 Aug 10;326(9):1-12. http://www.ncbi.nlm.nih.gov/pubmed/34375394?tool=bestpractice.com [64]Finfer S, Micallef S, Hammond N, et al. Balanced multielectrolyte solution versus saline in critically ill adults. N Engl J Med. 2022 Mar 3;386(9):815-26. http://www.ncbi.nlm.nih.gov/pubmed/35041780?tool=bestpractice.com Check local protocols for specific recommendations on fluid choice.
Practical tip
Be aware that large volumes of normal saline as the sole fluid for resuscitation may lead to hyperchloraemic acidosis.
Also note that use of lactate-containing fluid in a patient with impaired liver metabolism may lead to a spuriously elevated lactate level, so results need to be interpreted with other markers of volume status.
Consider admission to the intensive care unit if the patient has:
Undergone surgical intervention for IE
Sepsis
Heart failure
Valvular dysfunction
Multi-organ failure.
Obtain blood cultures prior to starting antibiotic therapy; this is vital because one dose of an antibiotic often masks an underlying bacteraemia and delays appropriate therapy.
If the patient is unwell (e.g., with sepsis), do not delay empirical antibiotic therapy while waiting to take three sets of blood cultures.
When a micro-organism has been identified, repeat the blood cultures after 48 to 72 hours to check the effectiveness of treatment.[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com
Think ' Could this be sepsis?' based on acute deterioration in a patient with suspected infective endocarditis.[22]NHS England. Sepsis guidance implementation advice for adults. September 2017 [internet publication]. https://www.england.nhs.uk/wp-content/uploads/2017/09/sepsis-guidance-implementation-advice-for-adults.pdf [23]Royal College of Physicians. National early warning score (NEWS) 2: standardising the assessment of acute-illness severity in the NHS. December 2017 [internet publication]. https://www.rcplondon.ac.uk/projects/outputs/national-early-warning-score-news-2 [24]National Institute for Health and Care Excellence. Sepsis: recognition, diagnosis and early management. September 2017 [internet publication]. https://www.nice.org.uk/guidance/ng51 See Sepsis in adults.
+More info: Sepsis
Use a systematic approach, alongside your clinical judgement, for assessment; urgently consult a senior clinical decision-maker (ST4 level doctor in the UK) if you suspect sepsis.[22]NHS England. Sepsis guidance implementation advice for adults. September 2017 [internet publication]. https://www.england.nhs.uk/wp-content/uploads/2017/09/sepsis-guidance-implementation-advice-for-adults.pdf [24]National Institute for Health and Care Excellence. Sepsis: recognition, diagnosis and early management. September 2017 [internet publication]. https://www.nice.org.uk/guidance/ng51 [25]Nutbeam T, Daniels R; The UK Sepsis Trust. Professional resources: clinical [internet publication]. https://sepsistrust.org/professional-resources/clinical [26]Academy of Medical Royal Colleges. Statement on the initial antimicrobial treatment of sepsis V2.0. Oct 2022 [internet publication] https://www.aomrc.org.uk/reports-guidance/statement-on-the-initial-antimicrobial-treatment-of-sepsis-v2-0
Refer to local guidelines for the recommended approach at your institution for assessment and management of the patient with suspected sepsis.
Refer any patient with suspected or confirmed IE for multidisciplinary evaluation. Ideally this will be within a specific endocarditis team, if available, including a cardiologist who is an accredited specialist in echocardiography (or a cardiologist and an additional accredited specialist in echocardiography who can be a cardiologist or clinical physiologist/scientist), a cardiac surgeon, an infectious disease or microbiology specialist, a neurologist, and a neurosurgeon.[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com [50]Sandoe JAT, Ahmed F, Arumugam P, et al. Expert consensus recommendations for the provision of infective endocarditis services: updated guidance from the Joint British Societies. Heart. 2023 Aug 11;109(17):e2. https://www.doi.org/10.1136/heartjnl-2022-321791 http://www.ncbi.nlm.nih.gov/pubmed/36898706?tool=bestpractice.com
Decisions on anticoagulant and antiplatelet therapy should be made on an individual basis by the multidisciplinary endocarditis team, if available.[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com
empirical broad-spectrum antibiotic therapy
Treatment recommended for ALL patients in selected patient group
Once blood cultures have been collected, promptly start broad-spectrum antibiotic therapy until sensitivities are known.[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com
If the patient is unwell (e.g., with sepsis), do not delay empirical antibiotic therapy while waiting to take three sets of blood cultures.
Check local guidance and seek advice from an infectious disease or microbiology specialist; recommended empirical regimens may differ between regions.[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com [36]Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation. 2015 Oct 13;132(15):1435-86. http://circ.ahajournals.org/content/132/15/1435.full http://www.ncbi.nlm.nih.gov/pubmed/26373316?tool=bestpractice.com [50]Sandoe JAT, Ahmed F, Arumugam P, et al. Expert consensus recommendations for the provision of infective endocarditis services: updated guidance from the Joint British Societies. Heart. 2023 Aug 11;109(17):e2. https://www.doi.org/10.1136/heartjnl-2022-321791 http://www.ncbi.nlm.nih.gov/pubmed/36898706?tool=bestpractice.com
The following factors should be taken into account when choosing the most appropriate empirical antibiotics:[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com [36]Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation. 2015 Oct 13;132(15):1435-86. http://circ.ahajournals.org/content/132/15/1435.full http://www.ncbi.nlm.nih.gov/pubmed/26373316?tool=bestpractice.com
Whether the patient has received previous antibiotic therapy
Whether the infection involves a native or prosthetic valve
If a prosthetic valve is involved, when the patient had surgery
Local epidemiology and knowledge of antibiotic-resistant and culture-negative pathogens
Where the infection was acquired (community, nosocomial, or non-nosocomial healthcare-associated).
Adjust antibiotic therapy accordingly once blood culture results are known (usually within 48 hours).[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com See Native valve: confirmed infective endocarditis and Prosthetic valve: confirmed infective endocarditis below.
surgery
Additional treatment recommended for SOME patients in selected patient group
Urgently refer any patient with acute heart failure for emergency surgery if they have persistent pulmonary oedema or cardiogenic shock despite medical therapy.[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com Give intravenous diuretics to manage pulmonary oedema prior to the surgery. See Acute heart failure.
Timing of surgical intervention should be decided by a multidisciplinary endocarditis team, if available.[50]Sandoe JAT, Ahmed F, Arumugam P, et al. Expert consensus recommendations for the provision of infective endocarditis services: updated guidance from the Joint British Societies. Heart. 2023 Aug 11;109(17):e2. https://www.doi.org/10.1136/heartjnl-2022-321791 http://www.ncbi.nlm.nih.gov/pubmed/36898706?tool=bestpractice.com [83]Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021 Feb 2;143(5):e35-71. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000932 http://www.ncbi.nlm.nih.gov/pubmed/33332149?tool=bestpractice.com
Indications for surgery include:[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com
Heart failure with:
Cardiogenic shock or pulmonary oedema (requires emergency surgery), or
Poor haemodynamic tolerance (requires urgent surgery)
Uncontrolled infection with:
Local complications (e.g., abscess, false aneurysm, fistula, enlarging vegetation)
Persistent positive blood cultures (despite appropriate antibiotic therapy for more than 1 week)
Resistant bacteria or fungi
Prosthetic valve endocarditis caused by Staphylococcus aureus or non-HACEK gram-negative bacilli
High risk of embolism or established embolism:
Vegetation ≥10 mm and emboli despite appropriate antibiotic therapy
Vegetation ≥10 mm and another reason for surgery (e.g., patients with significant valvular dysfunction, whether a direct result of endocarditis process or not)
Vegetation ≥10 mm and no evidence of embolus.
Temporary cardiac pacing is recommended if the patient has atrioventricular block secondary to aortic root abscess.
The aims of surgery are to remove infected tissue completely and to repair or replace the affected valves, thus restoring cardiac anatomy.
native valve: confirmed infective endocarditis
beta-lactam ± gentamicin; vancomycin
Cure rates of >95% can be achieved in patients treated with parenteral penicillin or ceftriaxone for IE caused by penicillin-susceptible oral streptococci or Streptococcus gallolyticus.[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com [36]Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation. 2015 Oct 13;132(15):1435-86. http://circ.ahajournals.org/content/132/15/1435.full http://www.ncbi.nlm.nih.gov/pubmed/26373316?tool=bestpractice.com Treatment consists of either beta-lactam (e.g., benzylpenicillin, amoxicillin, ceftriaxone) monotherapy for 4 weeks or a beta-lactam plus gentamicin for 2 weeks.[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com [36]Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation. 2015 Oct 13;132(15):1435-86. http://circ.ahajournals.org/content/132/15/1435.full http://www.ncbi.nlm.nih.gov/pubmed/26373316?tool=bestpractice.com
The 2-week regimen is only recommended if the patient has non-complicated native valve endocarditis and normal renal function.
The 4-week regimen should be used if the patient is >65 years of age, or has renal or cranial nerve VIII impairment.[36]Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation. 2015 Oct 13;132(15):1435-86. http://circ.ahajournals.org/content/132/15/1435.full http://www.ncbi.nlm.nih.gov/pubmed/26373316?tool=bestpractice.com
Netilmicin is recommended as an alternative to gentamicin by the European Society of Cardiology; however, it is not available in the UK and some other European countries.[36]Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation. 2015 Oct 13;132(15):1435-86. http://circ.ahajournals.org/content/132/15/1435.full http://www.ncbi.nlm.nih.gov/pubmed/26373316?tool=bestpractice.com
If the patient reports a penicillin allergy, determine the timing, extent, and nature of any previous reaction.[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com
In general, if the patient has a history of type I hypersensitivity anaphylactoid reactions or severe excoriating rashes, do not give penicillins or cephalosporins (10% to 15% cross-reactivity).
If the patient has a low-risk penicillin allergy, consider giving a single dose of a penicillin or cephalosporin while monitoring the patient closely.[82]Chua KYL, Vogrin S, Bury S, et al. The penicillin allergy delabeling program: a multicenter whole-of-hospital health services intervention and comparative effectiveness study. Clin Infect Dis. 2021 Aug 2;73(3):487-96. https://academic.oup.com/cid/article/73/3/487/5879938 http://www.ncbi.nlm.nih.gov/pubmed/32756983?tool=bestpractice.com A low-risk penicillin allergy includes:[82]Chua KYL, Vogrin S, Bury S, et al. The penicillin allergy delabeling program: a multicenter whole-of-hospital health services intervention and comparative effectiveness study. Clin Infect Dis. 2021 Aug 2;73(3):487-96. https://academic.oup.com/cid/article/73/3/487/5879938 http://www.ncbi.nlm.nih.gov/pubmed/32756983?tool=bestpractice.com
Unknown reaction >10 years previously
Type A adverse drug reaction (pharmacologically predictable intolerance) where direct de-labelling was not accepted by the patient
History of an unspecified childhood rash, localised injection-site reaction (only), or maculopapular exanthem >10 years ago.
Vancomycin monotherapy for 4 weeks is recommended if the patient is unable to tolerate penicillin (e.g., type I hypersensitivity reaction).[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com [36]Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation. 2015 Oct 13;132(15):1435-86. http://circ.ahajournals.org/content/132/15/1435.full http://www.ncbi.nlm.nih.gov/pubmed/26373316?tool=bestpractice.com
If the patient is receiving treatment with aminoglycosides, monitor renal and liver function, and for possible ototoxicity continuously (before, during, and after treatment). Also monitor serum aminoglycoside level during treatment.[36]Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation. 2015 Oct 13;132(15):1435-86. http://circ.ahajournals.org/content/132/15/1435.full http://www.ncbi.nlm.nih.gov/pubmed/26373316?tool=bestpractice.com [74]Medicines and Healthcare products Regulatory Agency. Aminoglycosides (gentamicin, amikacin, tobramycin, and neomycin): increased risk of deafness in patients with mitochondrial mutations. January 2021 [internet publication]. https://www.gov.uk/drug-safety-update/aminoglycosides-gentamicin-amikacin-tobramycin-and-neomycin-increased-risk-of-deafness-in-patients-with-mitochondrial-mutations
The UK-based Medicines and Healthcare products Regulatory Agency has issued a drug safety alert about the increased risk of deafness associated with aminoglycoside treatment in patients with mitochondrial mutations.[74]Medicines and Healthcare products Regulatory Agency. Aminoglycosides (gentamicin, amikacin, tobramycin, and neomycin): increased risk of deafness in patients with mitochondrial mutations. January 2021 [internet publication]. https://www.gov.uk/drug-safety-update/aminoglycosides-gentamicin-amikacin-tobramycin-and-neomycin-increased-risk-of-deafness-in-patients-with-mitochondrial-mutations
Follow your local protocols on genetic testing for mitochondrial mutations. Particularly consider mitochondrial mutation screening if the patient has a maternal history of deafness or mitochondrial mutations, or is having long-term or recurrent aminoglycoside treatment. Do not delay urgent antibiotic treatment for genetic testing.[74]Medicines and Healthcare products Regulatory Agency. Aminoglycosides (gentamicin, amikacin, tobramycin, and neomycin): increased risk of deafness in patients with mitochondrial mutations. January 2021 [internet publication]. https://www.gov.uk/drug-safety-update/aminoglycosides-gentamicin-amikacin-tobramycin-and-neomycin-increased-risk-of-deafness-in-patients-with-mitochondrial-mutations
Primary options
benzylpenicillin sodium: 7.2 to 14.4 g/day intravenously given in divided doses every 4 hours for 4 weeks
OR
amoxicillin: 100-200 mg/kg/day intravenously given in divided doses every 4-6 hours for 4 weeks
OR
ceftriaxone: 2 g intravenously/intramuscularly every 24 hours for 4 weeks
OR
benzylpenicillin sodium: 7.2 to 14.4 g/day intravenously given in divided doses every 4 hours for 2 weeks
or
amoxicillin: 100-200 mg/kg/day intravenously given in divided doses every 4-6 hours for 2 weeks
or
ceftriaxone: 2 g intravenously/intramuscularly every 24 hours for 2 weeks
-- AND --
gentamicin: 3 mg/kg intravenously/intramuscularly every 24 hours for 2 weeks
More gentamicinAdjust dose according to serum gentamicin level.
Secondary options
vancomycin: 30 mg/kg/day intravenously given in divided doses every 12 hours for 4 weeks
More vancomycinAdjust dose according to serum vancomycin level.
These drug options and doses relate to a patient with no comorbidities.
Primary options
benzylpenicillin sodium: 7.2 to 14.4 g/day intravenously given in divided doses every 4 hours for 4 weeks
OR
amoxicillin: 100-200 mg/kg/day intravenously given in divided doses every 4-6 hours for 4 weeks
OR
ceftriaxone: 2 g intravenously/intramuscularly every 24 hours for 4 weeks
OR
benzylpenicillin sodium: 7.2 to 14.4 g/day intravenously given in divided doses every 4 hours for 2 weeks
or
amoxicillin: 100-200 mg/kg/day intravenously given in divided doses every 4-6 hours for 2 weeks
or
ceftriaxone: 2 g intravenously/intramuscularly every 24 hours for 2 weeks
-- AND --
gentamicin: 3 mg/kg intravenously/intramuscularly every 24 hours for 2 weeks
More gentamicinAdjust dose according to serum gentamicin level.
Secondary options
vancomycin: 30 mg/kg/day intravenously given in divided doses every 12 hours for 4 weeks
More vancomycinAdjust dose according to serum vancomycin level.
Drug choice, dose and interactions may be affected by the patient's comorbidities. Check your local drug formulary.
Show drug information for a patient with no comorbidities
Primary options
benzylpenicillin sodium
OR
amoxicillin
OR
ceftriaxone
OR
benzylpenicillin sodium
or
amoxicillin
or
ceftriaxone
-- AND --
gentamicin
Secondary options
vancomycin
surgery
Additional treatment recommended for SOME patients in selected patient group
Many patients require surgery. Timing of surgical intervention should be decided by a multidisciplinary endocarditis team, if available.[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com [50]Sandoe JAT, Ahmed F, Arumugam P, et al. Expert consensus recommendations for the provision of infective endocarditis services: updated guidance from the Joint British Societies. Heart. 2023 Aug 11;109(17):e2. https://www.doi.org/10.1136/heartjnl-2022-321791 http://www.ncbi.nlm.nih.gov/pubmed/36898706?tool=bestpractice.com [83]Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021 Feb 2;143(5):e35-71. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000932 http://www.ncbi.nlm.nih.gov/pubmed/33332149?tool=bestpractice.com
Indications for surgery include:[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com
Heart failure with:
Cardiogenic shock or pulmonary oedema (requires emergency surgery), or
Poor haemodynamic tolerance (requires urgent surgery)
Uncontrolled infection with:
Local complications (e.g., abscess, false aneurysm, fistula, enlarging vegetation)
Persistent positive blood cultures (despite appropriate antibiotic therapy for more than 1 week)
Resistant bacteria or fungi
Prosthetic valve endocarditis caused by Staphylococcus aureus or non-HACEK gram-negative bacilli
High risk of embolism or established embolism:
Vegetation ≥10 mm and emboli despite appropriate antibiotic therapy
Vegetation ≥10 mm and another reason for surgery (e.g., patients with significant valvular dysfunction, whether a direct result of endocarditis process or not)
Vegetation ≥10 mm and no evidence of embolus.
Temporary cardiac pacing is recommended if the patient has atrioventricular block secondary to aortic root abscess.
The aims of surgery are to remove infected tissue completely and to repair or replace the affected valves, thus restoring cardiac anatomy.
beta-lactam + gentamicin; vancomycin
The incidence of streptococci with penicillin resistance is increasing.[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com If the patient has streptococcal endocarditis with increased antibiotic exposure or relative resistance to penicillin, a beta-lactam (e.g., benzylpenicillin, amoxicillin, ceftriaxone) for 4 weeks plus gentamicin for 2 weeks is the recommended regimen.[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com
If the patient reports a penicillin allergy, determine the timing, extent, and nature of any previous reaction.[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com
In general, if the patient has a history of type I hypersensitivity anaphylactoid reactions or severe excoriating rashes, do not give penicillins or cephalosporins (10% to 15% cross-reactivity).
If the patient has a low-risk penicillin allergy, consider giving a single dose of a penicillin or cephalosporin while monitoring the patient closely.[82]Chua KYL, Vogrin S, Bury S, et al. The penicillin allergy delabeling program: a multicenter whole-of-hospital health services intervention and comparative effectiveness study. Clin Infect Dis. 2021 Aug 2;73(3):487-96. https://academic.oup.com/cid/article/73/3/487/5879938 http://www.ncbi.nlm.nih.gov/pubmed/32756983?tool=bestpractice.com A low-risk penicillin allergy includes:[82]Chua KYL, Vogrin S, Bury S, et al. The penicillin allergy delabeling program: a multicenter whole-of-hospital health services intervention and comparative effectiveness study. Clin Infect Dis. 2021 Aug 2;73(3):487-96. https://academic.oup.com/cid/article/73/3/487/5879938 http://www.ncbi.nlm.nih.gov/pubmed/32756983?tool=bestpractice.com
Unknown reaction >10 years previously
Type A adverse drug reaction (pharmacologically predictable intolerance) where direct de-labelling was not accepted by the patient
History of an unspecified childhood rash, localised injection-site reaction (only), or maculopapular exanthem >10 years ago.
Vancomycin for 4 weeks is recommended if the patient is unable to tolerate penicillin (e.g., type I hypersensitivity reaction).[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com
Primary options
benzylpenicillin sodium: 7.2 to 14.4 g/day intravenously given in divided doses every 4 hours for 4 weeks
or
amoxicillin: 12 g/day intravenously given in divided doses every 4 hours for 4 weeks
or
ceftriaxone: 2 g intravenously/intramuscularly every 24 hours for 4 weeks
-- AND --
gentamicin: 3 mg/kg intravenously/intramuscularly every 24 hours for 2 weeks
More gentamicinAdjust dose according to serum gentamicin level.
Secondary options
vancomycin: 30 mg/kg/day intravenously given in divided doses every 12 hours for 4 weeks
More vancomycinAdjust dose according to serum vancomycin level.
These drug options and doses relate to a patient with no comorbidities.
Primary options
benzylpenicillin sodium: 7.2 to 14.4 g/day intravenously given in divided doses every 4 hours for 4 weeks
or
amoxicillin: 12 g/day intravenously given in divided doses every 4 hours for 4 weeks
or
ceftriaxone: 2 g intravenously/intramuscularly every 24 hours for 4 weeks
-- AND --
gentamicin: 3 mg/kg intravenously/intramuscularly every 24 hours for 2 weeks
More gentamicinAdjust dose according to serum gentamicin level.
Secondary options
vancomycin: 30 mg/kg/day intravenously given in divided doses every 12 hours for 4 weeks
More vancomycinAdjust dose according to serum vancomycin level.
Drug choice, dose and interactions may be affected by the patient's comorbidities. Check your local drug formulary.
Show drug information for a patient with no comorbidities
Primary options
benzylpenicillin sodium
or
amoxicillin
or
ceftriaxone
-- AND --
gentamicin
Secondary options
vancomycin
surgery
Additional treatment recommended for SOME patients in selected patient group
Many patients require surgery. Timing of surgical intervention should be decided by a multidisciplinary endocarditis team, if available.[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com [50]Sandoe JAT, Ahmed F, Arumugam P, et al. Expert consensus recommendations for the provision of infective endocarditis services: updated guidance from the Joint British Societies. Heart. 2023 Aug 11;109(17):e2. https://www.doi.org/10.1136/heartjnl-2022-321791 http://www.ncbi.nlm.nih.gov/pubmed/36898706?tool=bestpractice.com [83]Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021 Feb 2;143(5):e35-71. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000932 http://www.ncbi.nlm.nih.gov/pubmed/33332149?tool=bestpractice.com
Indications for surgery include:[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com
Heart failure with:
Cardiogenic shock or pulmonary oedema (requires emergency surgery), or
Poor haemodynamic tolerance (requires urgent surgery)
Uncontrolled infection with:
Local complications (e.g., abscess, false aneurysm, fistula, enlarging vegetation)
Persistent positive blood cultures (despite appropriate antibiotic therapy for more than 1 week)
Resistant bacteria or fungi
Prosthetic valve endocarditis caused by Staphylococcus aureus or non-HACEK gram-negative bacilli
High risk of embolism or established embolism:
Vegetation ≥10 mm and emboli despite appropriate antibiotic therapy
Vegetation ≥10 mm and another reason for surgery (e.g., patients with significant valvular dysfunction, whether a direct result of endocarditis process or not)
Vegetation ≥10 mm and no evidence of embolus.
Temporary cardiac pacing is recommended if the patient has atrioventricular block secondary to aortic root abscess.
The aims of surgery are to remove infected tissue completely and to repair or replace the affected valves, thus restoring cardiac anatomy.
1st line – beta-lactam; daptomycin + ceftaroline or fosfomycin
beta-lactam; daptomycin + ceftaroline or fosfomycin
A beta-lactam (e.g., flucloxacillin, cefazolin) is the treatment of choice in oxacillin-susceptible strains.[36]Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation. 2015 Oct 13;132(15):1435-86. http://circ.ahajournals.org/content/132/15/1435.full http://www.ncbi.nlm.nih.gov/pubmed/26373316?tool=bestpractice.com [70]Weis S, Kesselmeier M, Davis JS, et al. Cefazolin versus anti-staphylococcal penicillins for the treatment of patients with Staphylococcus aureus bacteraemia. Clin Microbiol Infect. 2019 Jul;25(7):818-27. https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(19)30112-0/fulltext http://www.ncbi.nlm.nih.gov/pubmed/30928559?tool=bestpractice.com
Cefazolin is recommended particularly if the patient has renal impairment[36]Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation. 2015 Oct 13;132(15):1435-86. http://circ.ahajournals.org/content/132/15/1435.full http://www.ncbi.nlm.nih.gov/pubmed/26373316?tool=bestpractice.com [70]Weis S, Kesselmeier M, Davis JS, et al. Cefazolin versus anti-staphylococcal penicillins for the treatment of patients with Staphylococcus aureus bacteraemia. Clin Microbiol Infect. 2019 Jul;25(7):818-27. https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(19)30112-0/fulltext http://www.ncbi.nlm.nih.gov/pubmed/30928559?tool=bestpractice.com
Staphylococcal endocarditis is an increasingly recognised entity, due to high rates of hospital exposure and the development of resistant organisms.
If the patient reports a penicillin allergy, determine the timing, extent, and nature of any previous reaction.[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com
In general, if the patient has a history of type I hypersensitivity anaphylactoid reactions or severe excoriating rashes, do not give penicillins or cephalosporins (10% to 15% cross-reactivity).
If the patient has a low-risk penicillin allergy, consider giving a single dose of a penicillin or cephalosporin while monitoring the patient closely.[82]Chua KYL, Vogrin S, Bury S, et al. The penicillin allergy delabeling program: a multicenter whole-of-hospital health services intervention and comparative effectiveness study. Clin Infect Dis. 2021 Aug 2;73(3):487-96. https://academic.oup.com/cid/article/73/3/487/5879938 http://www.ncbi.nlm.nih.gov/pubmed/32756983?tool=bestpractice.com A low-risk penicillin allergy includes:[82]Chua KYL, Vogrin S, Bury S, et al. The penicillin allergy delabeling program: a multicenter whole-of-hospital health services intervention and comparative effectiveness study. Clin Infect Dis. 2021 Aug 2;73(3):487-96. https://academic.oup.com/cid/article/73/3/487/5879938 http://www.ncbi.nlm.nih.gov/pubmed/32756983?tool=bestpractice.com
Unknown reaction >10 years previously
Type A adverse drug reaction (pharmacologically predictable intolerance) where direct de-labelling was not accepted by the patient
History of an unspecified childhood rash, localised injection-site reaction (only), or maculopapular exanthem >10 years ago.
Cefazolin, or daptomycin combined with ceftaroline or fosfomycin, is recommended if the patient has an oxacillin-resistant strain or is unable to tolerate penicillin (e.g., type I hypersensitivity reaction). The recommended treatment course is 4 to 6 weeks.[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com [36]Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation. 2015 Oct 13;132(15):1435-86. http://circ.ahajournals.org/content/132/15/1435.full http://www.ncbi.nlm.nih.gov/pubmed/26373316?tool=bestpractice.com
Staphylococcus aureus is the most common cause of endocarditis in patients who use intravenous drugs. If these patients have right-sided endocarditis, gentamicin has been shown to increase the rate of microbial killing when used in combination with a beta-lactam. However, aminoglycosides are no longer recommended in this scenario due to the increased risk of nephrotoxicity.[72]Korzeniowski O, Sande MA. Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts: a prospective study. Ann Intern Med. 1982 Oct;97(4):496-503. http://www.ncbi.nlm.nih.gov/pubmed/6751182?tool=bestpractice.com [73]Cosgrove SE, Vigliani GA, Fowler VG Jr., et al. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin Infect Dis. 2009 Mar 15;48(6):713-21. http://cid.oxfordjournals.org/content/48/6/713.long http://www.ncbi.nlm.nih.gov/pubmed/19207079?tool=bestpractice.com
Primary options
flucloxacillin: 12 g/day intravenously given in divided doses every 4-6 hours for 4-6 weeks
OR
cefazolin: 6 g/day intravenously given in divided doses every 8 hours for 4-6 weeks
Secondary options
daptomycin: 10 mg/kg intravenously every 24 hours for 4-6 weeks
-- AND --
ceftaroline: 1800 mg/day intravenously given in divided doses every 8 hours for 4-6 weeks
or
fosfomycin: 8-12 g/day intravenously given in divided doses every 6 hours for 4-6 weeks
These drug options and doses relate to a patient with no comorbidities.
Primary options
flucloxacillin: 12 g/day intravenously given in divided doses every 4-6 hours for 4-6 weeks
OR
cefazolin: 6 g/day intravenously given in divided doses every 8 hours for 4-6 weeks
Secondary options
daptomycin: 10 mg/kg intravenously every 24 hours for 4-6 weeks
-- AND --
ceftaroline: 1800 mg/day intravenously given in divided doses every 8 hours for 4-6 weeks
or
fosfomycin: 8-12 g/day intravenously given in divided doses every 6 hours for 4-6 weeks
Drug choice, dose and interactions may be affected by the patient's comorbidities. Check your local drug formulary.
Show drug information for a patient with no comorbidities
Primary options
flucloxacillin
OR
cefazolin
Secondary options
daptomycin
-- AND --
ceftaroline
or
fosfomycin
surgery
Additional treatment recommended for SOME patients in selected patient group
Many patients require surgery. Timing of surgical intervention should be decided by a multidisciplinary endocarditis team, if available.[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com [50]Sandoe JAT, Ahmed F, Arumugam P, et al. Expert consensus recommendations for the provision of infective endocarditis services: updated guidance from the Joint British Societies. Heart. 2023 Aug 11;109(17):e2. https://www.doi.org/10.1136/heartjnl-2022-321791 http://www.ncbi.nlm.nih.gov/pubmed/36898706?tool=bestpractice.com [83]Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021 Feb 2;143(5):e35-71. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000932 http://www.ncbi.nlm.nih.gov/pubmed/33332149?tool=bestpractice.com
Indications for surgery include:[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com
Heart failure with:
Cardiogenic shock or pulmonary oedema (requires emergency surgery), or
Poor haemodynamic tolerance (requires urgent surgery)
Uncontrolled infection with:
Local complications (e.g., abscess, false aneurysm, fistula, enlarging vegetation)
Persistent positive blood cultures (despite appropriate antibiotic therapy for more than 1 week)
Resistant bacteria or fungi
Prosthetic valve endocarditis caused by Staphylococcus aureus or non-HACEK gram-negative bacilli
High risk of embolism or established embolism:
Vegetation ≥10 mm and emboli despite appropriate antibiotic therapy
Vegetation ≥10 mm and another reason for surgery (e.g., patients with significant valvular dysfunction, whether a direct result of endocarditis process or not)
Vegetation ≥10 mm and no evidence of embolus.
Temporary cardiac pacing is recommended if the patient has atrioventricular block secondary to aortic root abscess.
The aims of surgery are to remove infected tissue completely and to repair or replace the affected valves, thus restoring cardiac anatomy.
1st line – vancomycin; daptomycin + cloxacillin or ceftaroline or fosfomycin
vancomycin; daptomycin + cloxacillin or ceftaroline or fosfomycin
Vancomycin is the treatment of choice if the patient has methicillin-resistant staphylococcal endocarditis.[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com Daptomycin in combination with cloxacillin or ceftaroline or fosfomycin may be used if the patient has vancomycin resistance.[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com [36]Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation. 2015 Oct 13;132(15):1435-86. http://circ.ahajournals.org/content/132/15/1435.full http://www.ncbi.nlm.nih.gov/pubmed/26373316?tool=bestpractice.com
There may be regional differences in treatment duration (e.g., 4-6 weeks).[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com
Primary options
vancomycin: 30-60 mg/kg/day intravenously given in divided doses every 8-12 hours for 4-6 weeks
More vancomycinAdjust dose according to serum vancomycin level.
Secondary options
daptomycin: 10 mg/kg intravenously every 24 hours for 4-6 weeks
-- AND --
cloxacillin: 12 g/day intravenously given in divided doses every 4 hours for 4-6 weeks
or
ceftaroline: 1800 mg/day intravenously given in divided doses every 8 hours for 4-6 weeks
or
fosfomycin: 8-12 g/day intravenously given in divided doses every 6 hours for 4-6 weeks
These drug options and doses relate to a patient with no comorbidities.
Primary options
vancomycin: 30-60 mg/kg/day intravenously given in divided doses every 8-12 hours for 4-6 weeks
More vancomycinAdjust dose according to serum vancomycin level.
Secondary options
daptomycin: 10 mg/kg intravenously every 24 hours for 4-6 weeks
-- AND --
cloxacillin: 12 g/day intravenously given in divided doses every 4 hours for 4-6 weeks
or
ceftaroline: 1800 mg/day intravenously given in divided doses every 8 hours for 4-6 weeks
or
fosfomycin: 8-12 g/day intravenously given in divided doses every 6 hours for 4-6 weeks
Drug choice, dose and interactions may be affected by the patient's comorbidities. Check your local drug formulary.
Show drug information for a patient with no comorbidities
Primary options
vancomycin
Secondary options
daptomycin
-- AND --
cloxacillin
or
ceftaroline
or
fosfomycin
surgery
Additional treatment recommended for SOME patients in selected patient group
Many patients require surgery. Timing of surgical intervention should be decided by a multidisciplinary endocarditis team, if available.[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com [50]Sandoe JAT, Ahmed F, Arumugam P, et al. Expert consensus recommendations for the provision of infective endocarditis services: updated guidance from the Joint British Societies. Heart. 2023 Aug 11;109(17):e2. https://www.doi.org/10.1136/heartjnl-2022-321791 http://www.ncbi.nlm.nih.gov/pubmed/36898706?tool=bestpractice.com [83]Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021 Feb 2;143(5):e35-71. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000932 http://www.ncbi.nlm.nih.gov/pubmed/33332149?tool=bestpractice.com
Indications for surgery include:[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com
Heart failure with:
Cardiogenic shock or pulmonary oedema (requires emergency surgery), or
Poor haemodynamic tolerance (requires urgent surgery)
Uncontrolled infection with:
Local complications (e.g., abscess, false aneurysm, fistula, enlarging vegetation)
Persistent positive blood cultures (despite appropriate antibiotic therapy for more than 1 week)
Resistant bacteria or fungi
Prosthetic valve endocarditis caused by Staphylococcus aureus or non-HACEK gram-negative bacilli
High risk of embolism or established embolism:
Vegetation ≥10 mm and emboli despite appropriate antibiotic therapy
Vegetation ≥10 mm and another reason for surgery (e.g., patients with significant valvular dysfunction, whether a direct result of endocarditis process or not)
Vegetation ≥10 mm and no evidence of embolus.
Temporary cardiac pacing is recommended if the patient has atrioventricular block secondary to aortic root abscess.
The aims of surgery are to remove infected tissue completely and to repair or replace the affected valves, thus restoring cardiac anatomy.
1st line – amoxicillin or ampicillin + ceftriaxone or gentamicin
amoxicillin or ampicillin + ceftriaxone or gentamicin
If the patient has a beta-lactam or gentamicin-susceptible strain of enterococci, they should be treated with a beta-lactam (e.g., amoxicillin, ampicillin) plus ceftriaxone for 6 weeks or gentamicin for 2 weeks.
The combination of ampicillin or amoxicillin plus ceftriaxone for 6 weeks may also be used if the patient has an Enterococcus faecalis strain with high-level aminoglycoside resistance, although this treatment is not active against Enterococcus faecium.[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com [36]Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation. 2015 Oct 13;132(15):1435-86. http://circ.ahajournals.org/content/132/15/1435.full http://www.ncbi.nlm.nih.gov/pubmed/26373316?tool=bestpractice.com
If the patient reports a penicillin allergy, determine the timing, extent, and nature of any previous reaction.[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com
In general, if the patient has a history of type I hypersensitivity anaphylactoid reactions or severe excoriating rashes, do not give penicillins or cephalosporins (10% to 15% cross-reactivity).
If the patient has a low-risk penicillin allergy, consider giving a single dose of a penicillin or cephalosporin while monitoring the patient closely.[82]Chua KYL, Vogrin S, Bury S, et al. The penicillin allergy delabeling program: a multicenter whole-of-hospital health services intervention and comparative effectiveness study. Clin Infect Dis. 2021 Aug 2;73(3):487-96. https://academic.oup.com/cid/article/73/3/487/5879938 http://www.ncbi.nlm.nih.gov/pubmed/32756983?tool=bestpractice.com A low-risk penicillin allergy includes:[82]Chua KYL, Vogrin S, Bury S, et al. The penicillin allergy delabeling program: a multicenter whole-of-hospital health services intervention and comparative effectiveness study. Clin Infect Dis. 2021 Aug 2;73(3):487-96. https://academic.oup.com/cid/article/73/3/487/5879938 http://www.ncbi.nlm.nih.gov/pubmed/32756983?tool=bestpractice.com
Unknown reaction >10 years previously
Type A adverse drug reaction (pharmacologically predictable intolerance) where direct de-labelling was not accepted by the patient
History of an unspecified childhood rash, localised injection-site reaction (only), or maculopapular exanthem >10 years ago.
If the patient is receiving treatment with aminoglycosides, monitor renal and liver function, and for possible ototoxicity continuously (before, during, and after treatment). Also monitor serum aminoglycoside level during treatment.[36]Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation. 2015 Oct 13;132(15):1435-86. http://circ.ahajournals.org/content/132/15/1435.full http://www.ncbi.nlm.nih.gov/pubmed/26373316?tool=bestpractice.com [74]Medicines and Healthcare products Regulatory Agency. Aminoglycosides (gentamicin, amikacin, tobramycin, and neomycin): increased risk of deafness in patients with mitochondrial mutations. January 2021 [internet publication]. https://www.gov.uk/drug-safety-update/aminoglycosides-gentamicin-amikacin-tobramycin-and-neomycin-increased-risk-of-deafness-in-patients-with-mitochondrial-mutations
The UK-based Medicines and Healthcare products Regulatory Agency has issued a drug safety alert about the increased risk of deafness associated with aminoglycoside treatment in patients with mitochondrial mutations.[74]Medicines and Healthcare products Regulatory Agency. Aminoglycosides (gentamicin, amikacin, tobramycin, and neomycin): increased risk of deafness in patients with mitochondrial mutations. January 2021 [internet publication]. https://www.gov.uk/drug-safety-update/aminoglycosides-gentamicin-amikacin-tobramycin-and-neomycin-increased-risk-of-deafness-in-patients-with-mitochondrial-mutations
Follow your local protocols on genetic testing for mitochondrial mutations. Particularly consider mitochondrial mutation screening if the patient has a maternal history of deafness or mitochondrial mutations, or is having long-term or recurrent aminoglycoside treatment. Do not delay urgent antibiotic treatment for genetic testing.[74]Medicines and Healthcare products Regulatory Agency. Aminoglycosides (gentamicin, amikacin, tobramycin, and neomycin): increased risk of deafness in patients with mitochondrial mutations. January 2021 [internet publication]. https://www.gov.uk/drug-safety-update/aminoglycosides-gentamicin-amikacin-tobramycin-and-neomycin-increased-risk-of-deafness-in-patients-with-mitochondrial-mutations
Primary options
amoxicillin: 200 mg/kg/day intravenously given in divided doses every 4-6 hours for 6 weeks
or
ampicillin: 12 g/day intravenously given in divided doses every 4-6 hours for 6 weeks
-- AND --
ceftriaxone: 4 g/day intravenously given in divided doses every 12 hours for 6 weeks
or
gentamicin: 3 mg/kg intravenously/intramuscularly every 24 hours for 2 weeks
More gentamicinAdjust dose according to serum gentamicin level.
These drug options and doses relate to a patient with no comorbidities.
Primary options
amoxicillin: 200 mg/kg/day intravenously given in divided doses every 4-6 hours for 6 weeks
or
ampicillin: 12 g/day intravenously given in divided doses every 4-6 hours for 6 weeks
-- AND --
ceftriaxone: 4 g/day intravenously given in divided doses every 12 hours for 6 weeks
or
gentamicin: 3 mg/kg intravenously/intramuscularly every 24 hours for 2 weeks
More gentamicinAdjust dose according to serum gentamicin level.
Drug choice, dose and interactions may be affected by the patient's comorbidities. Check your local drug formulary.
Show drug information for a patient with no comorbidities
Primary options
amoxicillin
or
ampicillin
-- AND --
ceftriaxone
or
gentamicin
surgery
Additional treatment recommended for SOME patients in selected patient group
Many patients require surgery. Timing of surgical intervention should be decided by a multidisciplinary endocarditis team, if available.[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com [50]Sandoe JAT, Ahmed F, Arumugam P, et al. Expert consensus recommendations for the provision of infective endocarditis services: updated guidance from the Joint British Societies. Heart. 2023 Aug 11;109(17):e2. https://www.doi.org/10.1136/heartjnl-2022-321791 http://www.ncbi.nlm.nih.gov/pubmed/36898706?tool=bestpractice.com [83]Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021 Feb 2;143(5):e35-71. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000932 http://www.ncbi.nlm.nih.gov/pubmed/33332149?tool=bestpractice.com
Indications for surgery include:[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com
Heart failure with:
Cardiogenic shock or pulmonary oedema (requires emergency surgery), or
Poor haemodynamic tolerance (requires urgent surgery)
Uncontrolled infection with:
Local complications (e.g., abscess, false aneurysm, fistula, enlarging vegetation)
Persistent positive blood cultures (despite appropriate antibiotic therapy for more than 1 week)
Resistant bacteria or fungi
Prosthetic valve endocarditis caused by Staphylococcus aureus or non-HACEK gram-negative bacilli
High risk of embolism or established embolism:
Vegetation ≥10 mm and emboli despite appropriate antibiotic therapy
Vegetation ≥10 mm and another reason for surgery (e.g., patients with significant valvular dysfunction, whether a direct result of endocarditis process or not)
Vegetation ≥10 mm and no evidence of embolus.
Temporary cardiac pacing is recommended if the patient has atrioventricular block secondary to aortic root abscess.
The aims of surgery are to remove infected tissue completely and to repair or replace the affected valves, thus restoring cardiac anatomy.
vancomycin + gentamicin
If the patient has IE due to Enterococcus faecalis, these strains can produce an inducible beta-lactamase, although this is rare. The patient should be treated with vancomycin for 6 weeks and gentamicin for 2 weeks.[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com
The treatment of enterococcal endocarditis, similar to that of viridans group streptococci, is based on the sensitivities to penicillin. Enterococci, unlike the viridans group streptococci, are not usually killed by antibiotics, but merely inhibited.
If the patient is receiving treatment with aminoglycosides, monitor renal and liver function, and for possible ototoxicity continuously (before, during, and after treatment). Also monitor serum aminoglycoside level during treatment.[36]Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation. 2015 Oct 13;132(15):1435-86. http://circ.ahajournals.org/content/132/15/1435.full http://www.ncbi.nlm.nih.gov/pubmed/26373316?tool=bestpractice.com [74]Medicines and Healthcare products Regulatory Agency. Aminoglycosides (gentamicin, amikacin, tobramycin, and neomycin): increased risk of deafness in patients with mitochondrial mutations. January 2021 [internet publication]. https://www.gov.uk/drug-safety-update/aminoglycosides-gentamicin-amikacin-tobramycin-and-neomycin-increased-risk-of-deafness-in-patients-with-mitochondrial-mutations
The UK-based Medicines and Healthcare products Regulatory Agency has issued a drug safety alert about the increased risk of deafness associated with aminoglycoside treatment in patients with mitochondrial mutations.[74]Medicines and Healthcare products Regulatory Agency. Aminoglycosides (gentamicin, amikacin, tobramycin, and neomycin): increased risk of deafness in patients with mitochondrial mutations. January 2021 [internet publication]. https://www.gov.uk/drug-safety-update/aminoglycosides-gentamicin-amikacin-tobramycin-and-neomycin-increased-risk-of-deafness-in-patients-with-mitochondrial-mutations
Follow your local protocols on genetic testing for mitochondrial mutations. Particularly consider mitochondrial mutation screening if the patient has a maternal history of deafness or mitochondrial mutations, or is having long-term or recurrent aminoglycoside treatment. Do not delay urgent antibiotic treatment for genetic testing.[74]Medicines and Healthcare products Regulatory Agency. Aminoglycosides (gentamicin, amikacin, tobramycin, and neomycin): increased risk of deafness in patients with mitochondrial mutations. January 2021 [internet publication]. https://www.gov.uk/drug-safety-update/aminoglycosides-gentamicin-amikacin-tobramycin-and-neomycin-increased-risk-of-deafness-in-patients-with-mitochondrial-mutations
Primary options
vancomycin: 30 mg/kg/day intravenously given in divided doses every 12 hours for 6 weeks
and
gentamicin: 3 mg/kg intravenously/intramuscularly every 24 hours for 2 weeks
More gentamicinAdjust dose according to serum gentamicin level.
These drug options and doses relate to a patient with no comorbidities.
Primary options
vancomycin: 30 mg/kg/day intravenously given in divided doses every 12 hours for 6 weeks
and
gentamicin: 3 mg/kg intravenously/intramuscularly every 24 hours for 2 weeks
More gentamicinAdjust dose according to serum gentamicin level.
Drug choice, dose and interactions may be affected by the patient's comorbidities. Check your local drug formulary.
Show drug information for a patient with no comorbidities
Primary options
vancomycin
and
gentamicin
surgery
Additional treatment recommended for SOME patients in selected patient group
Many patients require surgery. Timing of surgical intervention should be decided by a multidisciplinary endocarditis team, if available.[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com [50]Sandoe JAT, Ahmed F, Arumugam P, et al. Expert consensus recommendations for the provision of infective endocarditis services: updated guidance from the Joint British Societies. Heart. 2023 Aug 11;109(17):e2. https://www.doi.org/10.1136/heartjnl-2022-321791 http://www.ncbi.nlm.nih.gov/pubmed/36898706?tool=bestpractice.com [83]Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021 Feb 2;143(5):e35-71. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000932 http://www.ncbi.nlm.nih.gov/pubmed/33332149?tool=bestpractice.com
Indications for surgery include:[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com
Heart failure with:
Cardiogenic shock or pulmonary oedema (requires emergency surgery), or
Poor haemodynamic tolerance (requires urgent surgery)
Uncontrolled infection with:
Local complications (e.g., abscess, false aneurysm, fistula, enlarging vegetation)
Persistent positive blood cultures (despite appropriate antibiotic therapy for more than 1 week)
Resistant bacteria or fungi
Prosthetic valve endocarditis caused by Staphylococcus aureus or non-HACEK gram-negative bacilli
High risk of embolism or established embolism:
Vegetation ≥10 mm and emboli despite appropriate antibiotic therapy
Vegetation ≥10 mm and another reason for surgery (e.g., patients with significant valvular dysfunction, whether a direct result of endocarditis process or not)
Vegetation ≥10 mm and no evidence of embolus.
Temporary cardiac pacing is recommended if the patient has atrioventricular block secondary to aortic root abscess.
The aims of surgery are to remove infected tissue completely and to repair or replace the affected valves, thus restoring cardiac anatomy.
daptomycin + beta-lactam or fosfomycin
If the patient has IE due to vancomycin-resistant enterococci, they should be treated with daptomycin combined with a beta-lactam (e.g., ampicillin, ertapenem, ceftaroline) or fosfomycin for 6 weeks.[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com
Primary options
daptomycin: 10-12 mg/kg intravenously every 24 hours
-- AND --
ampicillin: 300 mg/kg/day intravenously given in divided doses every 4-6 hours
or
fosfomycin: 12 g/day intravenously given in divided doses every 6 hours
or
ceftaroline: 1800 mg/day intravenously given in divided doses every 8 hours
or
ertapenem: 2 g intravenously/intramuscularly every 24 hours
These drug options and doses relate to a patient with no comorbidities.
Primary options
daptomycin: 10-12 mg/kg intravenously every 24 hours
-- AND --
ampicillin: 300 mg/kg/day intravenously given in divided doses every 4-6 hours
or
fosfomycin: 12 g/day intravenously given in divided doses every 6 hours
or
ceftaroline: 1800 mg/day intravenously given in divided doses every 8 hours
or
ertapenem: 2 g intravenously/intramuscularly every 24 hours
Drug choice, dose and interactions may be affected by the patient's comorbidities. Check your local drug formulary.
Show drug information for a patient with no comorbidities
Primary options
daptomycin
-- AND --
ampicillin
or
fosfomycin
or
ceftaroline
or
ertapenem
surgery
Additional treatment recommended for SOME patients in selected patient group
Many patients require surgery. Timing of surgical intervention should be decided by a multidisciplinary endocarditis team, if available.[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com [50]Sandoe JAT, Ahmed F, Arumugam P, et al. Expert consensus recommendations for the provision of infective endocarditis services: updated guidance from the Joint British Societies. Heart. 2023 Aug 11;109(17):e2. https://www.doi.org/10.1136/heartjnl-2022-321791 http://www.ncbi.nlm.nih.gov/pubmed/36898706?tool=bestpractice.com [83]Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021 Feb 2;143(5):e35-71. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000932 http://www.ncbi.nlm.nih.gov/pubmed/33332149?tool=bestpractice.com
Indications for surgery include:[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com
Heart failure with:
Cardiogenic shock or pulmonary oedema (requires emergency surgery), or
Poor haemodynamic tolerance (requires urgent surgery)
Uncontrolled infection with:
Local complications (e.g., abscess, false aneurysm, fistula, enlarging vegetation)
Persistent positive blood cultures (despite appropriate antibiotic therapy for more than 1 week)
Resistant bacteria or fungi
Prosthetic valve endocarditis caused by Staphylococcus aureus or non-HACEK gram-negative bacilli
High risk of embolism or established embolism:
Vegetation ≥10 mm and emboli despite appropriate antibiotic therapy
Vegetation ≥10 mm and another reason for surgery (e.g., patients with significant valvular dysfunction, whether a direct result of endocarditis process or not)
Vegetation ≥10 mm and no evidence of embolus.
Temporary cardiac pacing is recommended if the patient has atrioventricular block secondary to aortic root abscess.
The aims of surgery are to remove infected tissue completely and to repair or replace the affected valves, thus restoring cardiac anatomy.
1st line – consultation with infectious disease or microbiology specialist
consultation with infectious disease or microbiology specialist
Seek advice from an infectious disease or microbiology specialist if the patient has multi-resistance to aminoglycosides, beta-lactams, and vancomycin; this is very difficult to manage.
surgery
Additional treatment recommended for SOME patients in selected patient group
Many patients require surgery. Timing of surgical intervention should be decided by a multidisciplinary endocarditis team, if available.[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com [50]Sandoe JAT, Ahmed F, Arumugam P, et al. Expert consensus recommendations for the provision of infective endocarditis services: updated guidance from the Joint British Societies. Heart. 2023 Aug 11;109(17):e2. https://www.doi.org/10.1136/heartjnl-2022-321791 http://www.ncbi.nlm.nih.gov/pubmed/36898706?tool=bestpractice.com [83]Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021 Feb 2;143(5):e35-71. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000932 http://www.ncbi.nlm.nih.gov/pubmed/33332149?tool=bestpractice.com
Indications for surgery include:[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com
Heart failure with:
Cardiogenic shock or pulmonary oedema (requires emergency surgery), or
Poor haemodynamic tolerance (requires urgent surgery)
Uncontrolled infection with:
Local complications (e.g., abscess, false aneurysm, fistula, enlarging vegetation)
Persistent positive blood cultures (despite appropriate antibiotic therapy for more than 1 week)
Resistant bacteria or fungi
Prosthetic valve endocarditis caused by Staphylococcus aureus or non-HACEK gram-negative bacilli
High risk of embolism or established embolism:
Vegetation ≥10 mm and emboli despite appropriate antibiotic therapy
Vegetation ≥10 mm and another reason for surgery (e.g., patients with significant valvular dysfunction, whether a direct result of endocarditis process or not)
Vegetation ≥10 mm and no evidence of embolus.
Temporary cardiac pacing is recommended if the patient has atrioventricular block secondary to aortic root abscess.
The aims of surgery are to remove infected tissue completely and to repair or replace the affected valves, thus restoring cardiac anatomy.
1st line – ceftriaxone; ampicillin + gentamicin; ciprofloxacin
ceftriaxone; ampicillin + gentamicin; ciprofloxacin
Ceftriaxone is standard treatment if the patient has Haemophilus, Aggregatibacter (formerly Actinobacillus), Cardiobacterium, Eikenella, and Kingella (HACEK) IE, and should be continued for 4 weeks in native valve endocarditis.[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com
HACEK strains are also susceptible to other third-generation cephalosporins.[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com
Ampicillin should not be used as first-line therapy for treatment of HACEK endocarditis because some HACEK-group bacilli produce beta-lactamases and are increasingly ampicillin-resistant.[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com However, if they do not produce beta-lactamase, ampicillin (for 4 weeks) plus gentamicin (for 2 weeks) is an option.[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com
If the patient reports a penicillin allergy, determine the timing, extent, and nature of any previous reaction.[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com
In general, if the patient has a history of type I hypersensitivity anaphylactoid reactions or severe excoriating rashes, do not give penicillins or cephalosporins (10% to 15% cross-reactivity).
If the patient has a low-risk penicillin allergy, consider giving a single dose of a penicillin or cephalosporin while monitoring the patient closely.[82]Chua KYL, Vogrin S, Bury S, et al. The penicillin allergy delabeling program: a multicenter whole-of-hospital health services intervention and comparative effectiveness study. Clin Infect Dis. 2021 Aug 2;73(3):487-96. https://academic.oup.com/cid/article/73/3/487/5879938 http://www.ncbi.nlm.nih.gov/pubmed/32756983?tool=bestpractice.com A low-risk penicillin allergy includes:[82]Chua KYL, Vogrin S, Bury S, et al. The penicillin allergy delabeling program: a multicenter whole-of-hospital health services intervention and comparative effectiveness study. Clin Infect Dis. 2021 Aug 2;73(3):487-96. https://academic.oup.com/cid/article/73/3/487/5879938 http://www.ncbi.nlm.nih.gov/pubmed/32756983?tool=bestpractice.com
Unknown reaction >10 years previously
Type A adverse drug reaction (pharmacologically predictable intolerance) where direct de-labelling was not accepted by the patient
History of an unspecified childhood rash, localised injection-site reaction (only), or maculopapular exanthem >10 years ago.
HACEK strains are also susceptible to fluoroquinolones (e.g., ciprofloxacin), which are recommended if the patient is unable to tolerate penicillin (e.g., type I hypersensitivity reaction).[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com
The European Medicines Agency and the UK-based Medicines and Healthcare products Regulatory Agency have issued warnings that fluoroquinolones have been associated with disabling and potentially irreversible musculoskeletal or nervous system adverse effects.[76]European Medicines Agency. Quinolone- and fluoroquinolone-containing medicinal products. March 2019 [internet publication]. https://www.ema.europa.eu/en/medicines/human/referrals/quinolone-fluoroquinolone-containing-medicinal-products [77]Medicines and Healthcare products Regulatory Agency. Fluoroquinolone antibiotics: new restrictions and precautions for use due to very rare reports of disabling and potentially long-lasting or irreversible side effects. March 2019 [internet publication]. https://www.gov.uk/drug-safety-update/fluoroquinolone-antibiotics-new-restrictions-and-precautions-for-use-due-to-very-rare-reports-of-disabling-and-potentially-long-lasting-or-irreversible-side-effects
In addition, the US Food and Drug Administration has issued warnings about the increased risk of aortic dissection, significant hypoglycaemia, and mental health adverse effects in patients taking fluoroquinolones.[78]US Food and Drug Administration. FDA drug safety communication: FDA reinforces safety information about serious low blood sugar levels and mental health side effects with fluoroquinolone antibiotics; requires label changes. October 2018 [internet publication]. https://www.fda.gov/drugs/drug-safety-and-availability/fda-reinforces-safety-information-about-serious-low-blood-sugar-levels-and-mental-health-side [79]US Food and Drug Administration. FDA drug safety communication: FDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics in certain patients. December 2018 [internet publication]. https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-increased-risk-ruptures-or-tears-aorta-blood-vessel-fluoroquinolone-antibiotics
If the patient is receiving treatment with aminoglycosides, monitor renal and liver function, and for possible ototoxicity continuously (before, during, and after treatment). Also monitor serum aminoglycoside level during treatment.[36]Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation. 2015 Oct 13;132(15):1435-86. http://circ.ahajournals.org/content/132/15/1435.full http://www.ncbi.nlm.nih.gov/pubmed/26373316?tool=bestpractice.com [74]Medicines and Healthcare products Regulatory Agency. Aminoglycosides (gentamicin, amikacin, tobramycin, and neomycin): increased risk of deafness in patients with mitochondrial mutations. January 2021 [internet publication]. https://www.gov.uk/drug-safety-update/aminoglycosides-gentamicin-amikacin-tobramycin-and-neomycin-increased-risk-of-deafness-in-patients-with-mitochondrial-mutations
The UK-based Medicines and Healthcare products Regulatory Agency has issued a drug safety alert about the increased risk of deafness associated with aminoglycoside treatment in patients with mitochondrial mutations.[74]Medicines and Healthcare products Regulatory Agency. Aminoglycosides (gentamicin, amikacin, tobramycin, and neomycin): increased risk of deafness in patients with mitochondrial mutations. January 2021 [internet publication]. https://www.gov.uk/drug-safety-update/aminoglycosides-gentamicin-amikacin-tobramycin-and-neomycin-increased-risk-of-deafness-in-patients-with-mitochondrial-mutations
Follow your local protocols on genetic testing for mitochondrial mutations. Particularly consider mitochondrial mutation screening if the patient has a maternal history of deafness or mitochondrial mutations, or is having long-term or recurrent aminoglycoside treatment. Do not delay urgent antibiotic treatment for genetic testing.[74]Medicines and Healthcare products Regulatory Agency. Aminoglycosides (gentamicin, amikacin, tobramycin, and neomycin): increased risk of deafness in patients with mitochondrial mutations. January 2021 [internet publication]. https://www.gov.uk/drug-safety-update/aminoglycosides-gentamicin-amikacin-tobramycin-and-neomycin-increased-risk-of-deafness-in-patients-with-mitochondrial-mutations
Primary options
ceftriaxone: 2 g intravenously/intramuscularly every 24 hours for 4 weeks
Secondary options
ampicillin: 12 g/day intravenously given in divided doses every 4-6 hours for 4 weeks
and
gentamicin: 3 mg/kg/day intravenously/intramuscularly given in divided doses every 8-12 hours for 2 weeks
More gentamicinAdjust dose according to serum gentamicin level.
OR
ciprofloxacin: 400 mg intravenously every 8-12 hours for 4 weeks; 750 mg orally twice daily for 4 weeks
These drug options and doses relate to a patient with no comorbidities.
Primary options
ceftriaxone: 2 g intravenously/intramuscularly every 24 hours for 4 weeks
Secondary options
ampicillin: 12 g/day intravenously given in divided doses every 4-6 hours for 4 weeks
and
gentamicin: 3 mg/kg/day intravenously/intramuscularly given in divided doses every 8-12 hours for 2 weeks
More gentamicinAdjust dose according to serum gentamicin level.
OR
ciprofloxacin: 400 mg intravenously every 8-12 hours for 4 weeks; 750 mg orally twice daily for 4 weeks
Drug choice, dose and interactions may be affected by the patient's comorbidities. Check your local drug formulary.
Show drug information for a patient with no comorbidities
Primary options
ceftriaxone
Secondary options
ampicillin
and
gentamicin
OR
ciprofloxacin
surgery
Additional treatment recommended for SOME patients in selected patient group
Many patients require surgery. Timing of surgical intervention should be decided by a multidisciplinary endocarditis team, if available.[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com [50]Sandoe JAT, Ahmed F, Arumugam P, et al. Expert consensus recommendations for the provision of infective endocarditis services: updated guidance from the Joint British Societies. Heart. 2023 Aug 11;109(17):e2. https://www.doi.org/10.1136/heartjnl-2022-321791 http://www.ncbi.nlm.nih.gov/pubmed/36898706?tool=bestpractice.com [83]Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021 Feb 2;143(5):e35-71. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000932 http://www.ncbi.nlm.nih.gov/pubmed/33332149?tool=bestpractice.com
Indications for surgery include:[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com
Heart failure with:
Cardiogenic shock or pulmonary oedema (requires emergency surgery), or
Poor haemodynamic tolerance (requires urgent surgery)
Uncontrolled infection with:
Local complications (e.g., abscess, false aneurysm, fistula, enlarging vegetation)
Persistent positive blood cultures (despite appropriate antibiotic therapy for more than 1 week)
Resistant bacteria or fungi
Prosthetic valve endocarditis caused by Staphylococcus aureus or non-HACEK gram-negative bacilli
High risk of embolism or established embolism:
Vegetation ≥10 mm and emboli despite appropriate antibiotic therapy
Vegetation ≥10 mm and another reason for surgery (e.g., patients with significant valvular dysfunction, whether a direct result of endocarditis process or not)
Vegetation ≥10 mm and no evidence of embolus.
Temporary cardiac pacing is recommended if the patient has atrioventricular block secondary to aortic root abscess.
The aims of surgery are to remove infected tissue completely and to repair or replace the affected valves, thus restoring cardiac anatomy.
1st line – consultation with infectious disease or microbiology specialist
consultation with infectious disease or microbiology specialist
Seek advice from an infectious disease or microbiology specialist if the patient has IE due to a culture-negative (non-HACEK) micro-organism.
Various mechanisms of antibiotic resistance are found in non-HACEK organisms.
A variety of organisms are implicated in culture-negative (non-HACEK) endocarditis including Chlamydia species, Coxiella species, Bartonella species, Brucella species, and Legionella species.
surgery
Additional treatment recommended for SOME patients in selected patient group
Many patients require surgery. Timing of surgical intervention should be decided by a multidisciplinary endocarditis team, if available.[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com [50]Sandoe JAT, Ahmed F, Arumugam P, et al. Expert consensus recommendations for the provision of infective endocarditis services: updated guidance from the Joint British Societies. Heart. 2023 Aug 11;109(17):e2. https://www.doi.org/10.1136/heartjnl-2022-321791 http://www.ncbi.nlm.nih.gov/pubmed/36898706?tool=bestpractice.com [83]Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021 Feb 2;143(5):e35-71. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000932 http://www.ncbi.nlm.nih.gov/pubmed/33332149?tool=bestpractice.com
Indications for surgery include:[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com
Heart failure with:
Cardiogenic shock or pulmonary oedema (requires emergency surgery), or
Poor haemodynamic tolerance (requires urgent surgery)
Uncontrolled infection with:
Local complications (e.g., abscess, false aneurysm, fistula, enlarging vegetation)
Persistent positive blood cultures (despite appropriate antibiotic therapy for more than 1 week)
Resistant bacteria or fungi
Prosthetic valve endocarditis caused by Staphylococcus aureus or non-HACEK gram-negative bacilli
High risk of embolism or established embolism:
Vegetation ≥10 mm and emboli despite appropriate antibiotic therapy
Vegetation ≥10 mm and another reason for surgery (e.g., patients with significant valvular dysfunction, whether a direct result of endocarditis process or not)
Vegetation ≥10 mm and no evidence of embolus.
Temporary cardiac pacing is recommended if the patient has atrioventricular block secondary to aortic root abscess.
The aims of surgery are to remove infected tissue completely and to repair or replace the affected valves, thus restoring cardiac anatomy.
1st line – consultation with infectious disease or microbiology specialist
consultation with infectious disease or microbiology specialist
Seek early advice from an infectious disease or microbiology specialist if the patient has fungal IE.[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com Mortality is very high (>50%) .[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com
Be aware that fungal infections most frequently affect patients with prosthetic valves and those who are immunocompromised.
Patients who use intravenous drugs are also at increased risk of fungal IE.
The most common causative agents are Candida and Aspergillus.
Treatment includes valve replacement and antifungal therapy.[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com [80]Ellis ME, Al-Abdely H, Sandridge A, et al. Fungal endocarditis: evidence in the world literature, 1965-1995. Clin Infect Dis. 2001 Jan;32(1):50-62. http://cid.oxfordjournals.org/content/32/1/50.long http://www.ncbi.nlm.nih.gov/pubmed/11118386?tool=bestpractice.com
Early surgical intervention is essential to prevent complications of fungal endocarditis.[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com [88]Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016 Aug 15;63(4):e1-60. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4967602 http://www.ncbi.nlm.nih.gov/pubmed/27365388?tool=bestpractice.com
prosthetic valve: confirmed infective endocarditis
beta-lactam; vancomycin
Cure rates of >95% can be achieved in patients treated with parenteral penicillin or ceftriaxone for IE caused by penicillin-susceptible oral streptococci or Streptococcus gallolyticus.[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com [36]Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation. 2015 Oct 13;132(15):1435-86. http://circ.ahajournals.org/content/132/15/1435.full http://www.ncbi.nlm.nih.gov/pubmed/26373316?tool=bestpractice.com Treatment consists of beta-lactam (e.g., benzylpenicillin, amoxicillin, ceftriaxone) monotherapy for 6 weeks.[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com [36]Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation. 2015 Oct 13;132(15):1435-86. http://circ.ahajournals.org/content/132/15/1435.full http://www.ncbi.nlm.nih.gov/pubmed/26373316?tool=bestpractice.com
If the patient reports a penicillin allergy, determine the timing, extent, and nature of any previous reaction.[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com
In general, if the patient has a history of type I hypersensitivity anaphylactoid reactions or severe excoriating rashes, do not give penicillins or cephalosporins (10% to 15% cross-reactivity).
If the patient has a low-risk penicillin allergy, consider giving a single dose of a penicillin or cephalosporin while monitoring the patient closely.[82]Chua KYL, Vogrin S, Bury S, et al. The penicillin allergy delabeling program: a multicenter whole-of-hospital health services intervention and comparative effectiveness study. Clin Infect Dis. 2021 Aug 2;73(3):487-96. https://academic.oup.com/cid/article/73/3/487/5879938 http://www.ncbi.nlm.nih.gov/pubmed/32756983?tool=bestpractice.com A low-risk penicillin allergy includes:[82]Chua KYL, Vogrin S, Bury S, et al. The penicillin allergy delabeling program: a multicenter whole-of-hospital health services intervention and comparative effectiveness study. Clin Infect Dis. 2021 Aug 2;73(3):487-96. https://academic.oup.com/cid/article/73/3/487/5879938 http://www.ncbi.nlm.nih.gov/pubmed/32756983?tool=bestpractice.com
Unknown reaction >10 years previously
Type A adverse drug reaction (pharmacologically predictable intolerance) where direct de-labelling was not accepted by the patient
History of an unspecified childhood rash, localised injection-site reaction (only), or maculopapular exanthem >10 years ago.
Vancomycin monotherapy for 6 weeks is recommended if the patient is unable to tolerate penicillin (e.g., type I hypersensitivity reaction).[36]Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation. 2015 Oct 13;132(15):1435-86. http://circ.ahajournals.org/content/132/15/1435.full http://www.ncbi.nlm.nih.gov/pubmed/26373316?tool=bestpractice.com
If the patient is receiving treatment with aminoglycosides, monitor renal and liver function, and for possible ototoxicity continuously (before, during, and after treatment). Also monitor serum aminoglycoside level during treatment.[36]Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation. 2015 Oct 13;132(15):1435-86. http://circ.ahajournals.org/content/132/15/1435.full http://www.ncbi.nlm.nih.gov/pubmed/26373316?tool=bestpractice.com [74]Medicines and Healthcare products Regulatory Agency. Aminoglycosides (gentamicin, amikacin, tobramycin, and neomycin): increased risk of deafness in patients with mitochondrial mutations. January 2021 [internet publication]. https://www.gov.uk/drug-safety-update/aminoglycosides-gentamicin-amikacin-tobramycin-and-neomycin-increased-risk-of-deafness-in-patients-with-mitochondrial-mutations
The UK-based Medicines and Healthcare products Regulatory Agency has issued a drug safety alert about the increased risk of deafness associated with aminoglycoside treatment in patients with mitochondrial mutations.[74]Medicines and Healthcare products Regulatory Agency. Aminoglycosides (gentamicin, amikacin, tobramycin, and neomycin): increased risk of deafness in patients with mitochondrial mutations. January 2021 [internet publication]. https://www.gov.uk/drug-safety-update/aminoglycosides-gentamicin-amikacin-tobramycin-and-neomycin-increased-risk-of-deafness-in-patients-with-mitochondrial-mutations
Follow your local protocols on genetic testing for mitochondrial mutations. Particularly consider mitochondrial mutation screening if the patient has a maternal history of deafness or mitochondrial mutations, or is having long-term or recurrent aminoglycoside treatment. Do not delay urgent antibiotic treatment for genetic testing.[74]Medicines and Healthcare products Regulatory Agency. Aminoglycosides (gentamicin, amikacin, tobramycin, and neomycin): increased risk of deafness in patients with mitochondrial mutations. January 2021 [internet publication]. https://www.gov.uk/drug-safety-update/aminoglycosides-gentamicin-amikacin-tobramycin-and-neomycin-increased-risk-of-deafness-in-patients-with-mitochondrial-mutations
Primary options
benzylpenicillin sodium: 7.2 to 14.4 g/day intravenously given in divided doses every 4 hours for 6 weeks
OR
amoxicillin: 100-200 mg/kg/day intravenously given in divided doses every 4-6 hours for 6 weeks
OR
ceftriaxone: 2 g intravenously/intramuscularly every 24 hours for 6 weeks
Secondary options
vancomycin: 30 mg/kg/day intravenously given in divided doses every 12 hours for 6 weeks
More vancomycinAdjust dose according to serum vancomycin level.
These drug options and doses relate to a patient with no comorbidities.
Primary options
benzylpenicillin sodium: 7.2 to 14.4 g/day intravenously given in divided doses every 4 hours for 6 weeks
OR
amoxicillin: 100-200 mg/kg/day intravenously given in divided doses every 4-6 hours for 6 weeks
OR
ceftriaxone: 2 g intravenously/intramuscularly every 24 hours for 6 weeks
Secondary options
vancomycin: 30 mg/kg/day intravenously given in divided doses every 12 hours for 6 weeks
More vancomycinAdjust dose according to serum vancomycin level.
Drug choice, dose and interactions may be affected by the patient's comorbidities. Check your local drug formulary.
Show drug information for a patient with no comorbidities
Primary options
benzylpenicillin sodium
OR
amoxicillin
OR
ceftriaxone
Secondary options
vancomycin
surgery
Additional treatment recommended for SOME patients in selected patient group
Many patients require surgery. Timing of surgical intervention should be decided by a multidisciplinary endocarditis team, if available.[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com [50]Sandoe JAT, Ahmed F, Arumugam P, et al. Expert consensus recommendations for the provision of infective endocarditis services: updated guidance from the Joint British Societies. Heart. 2023 Aug 11;109(17):e2. https://www.doi.org/10.1136/heartjnl-2022-321791 http://www.ncbi.nlm.nih.gov/pubmed/36898706?tool=bestpractice.com [83]Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021 Feb 2;143(5):e35-71. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000932 http://www.ncbi.nlm.nih.gov/pubmed/33332149?tool=bestpractice.com
Indications for surgery include:[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com
Heart failure with:
Cardiogenic shock or pulmonary oedema (requires emergency surgery), or
Poor haemodynamic tolerance (requires urgent surgery)
Uncontrolled infection with:
Local complications (e.g., abscess, false aneurysm, fistula, enlarging vegetation)
Persistent positive blood cultures (despite appropriate antibiotic therapy for more than 1 week)
Resistant bacteria or fungi
Prosthetic valve endocarditis caused by Staphylococcus aureus or non-HACEK gram-negative bacilli
High risk of embolism or established embolism:
Vegetation ≥10 mm and emboli despite appropriate antibiotic therapy
Vegetation ≥10 mm and another reason for surgery (e.g., patients with significant valvular dysfunction, whether a direct result of endocarditis process or not)
Vegetation ≥10 mm and no evidence of embolus.
Temporary cardiac pacing is recommended if the patient has atrioventricular block secondary to aortic root abscess.
The aims of surgery are to remove infected tissue completely and to repair or replace the affected valves, thus restoring cardiac anatomy.
beta-lactam or vancomycin + gentamicin
The incidence of streptococci with penicillin resistance is increasing.[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com If the patient has streptococcal endocarditis with increased antibiotic exposure or relative resistance to penicillin, a beta-lactam (e.g., benzylpenicillin, amoxicillin, ceftriaxone) for 6 weeks plus gentamicin for 2 weeks is the recommended regimen.[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com
If the patient reports a penicillin allergy, determine the timing, extent, and nature of any previous reaction.[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com
In general, if the patient has a history of type I hypersensitivity anaphylactoid reactions or severe excoriating rashes, do not give penicillins or cephalosporins (10% to 15% cross-reactivity).
If the patient has a low-risk penicillin allergy, consider giving a single dose of a penicillin or cephalosporin while monitoring the patient closely.[82]Chua KYL, Vogrin S, Bury S, et al. The penicillin allergy delabeling program: a multicenter whole-of-hospital health services intervention and comparative effectiveness study. Clin Infect Dis. 2021 Aug 2;73(3):487-96. https://academic.oup.com/cid/article/73/3/487/5879938 http://www.ncbi.nlm.nih.gov/pubmed/32756983?tool=bestpractice.com A low-risk penicillin allergy includes:[82]Chua KYL, Vogrin S, Bury S, et al. The penicillin allergy delabeling program: a multicenter whole-of-hospital health services intervention and comparative effectiveness study. Clin Infect Dis. 2021 Aug 2;73(3):487-96. https://academic.oup.com/cid/article/73/3/487/5879938 http://www.ncbi.nlm.nih.gov/pubmed/32756983?tool=bestpractice.com
Unknown reaction >10 years previously
Type A adverse drug reaction (pharmacologically predictable intolerance) where direct de-labelling was not accepted by the patient
History of an unspecified childhood rash, localised injection-site reaction (only), or maculopapular exanthem >10 years ago.
Vancomycin for 6 weeks and gentamicin for 2 weeks is recommended if the patient is unable to tolerate penicillin (e.g., type I hypersensitivity reaction).[36]Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation. 2015 Oct 13;132(15):1435-86. http://circ.ahajournals.org/content/132/15/1435.full http://www.ncbi.nlm.nih.gov/pubmed/26373316?tool=bestpractice.com
If the patient is receiving treatment with aminoglycosides, monitor renal and liver function, and for possible ototoxicity continuously (before, during, and after treatment). Also monitor serum aminoglycoside level during treatment.[36]Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation. 2015 Oct 13;132(15):1435-86. http://circ.ahajournals.org/content/132/15/1435.full http://www.ncbi.nlm.nih.gov/pubmed/26373316?tool=bestpractice.com [74]Medicines and Healthcare products Regulatory Agency. Aminoglycosides (gentamicin, amikacin, tobramycin, and neomycin): increased risk of deafness in patients with mitochondrial mutations. January 2021 [internet publication]. https://www.gov.uk/drug-safety-update/aminoglycosides-gentamicin-amikacin-tobramycin-and-neomycin-increased-risk-of-deafness-in-patients-with-mitochondrial-mutations
The UK-based Medicines and Healthcare products Regulatory Agency has issued a drug safety alert about the increased risk of deafness associated with aminoglycoside treatment in patients with mitochondrial mutations.[74]Medicines and Healthcare products Regulatory Agency. Aminoglycosides (gentamicin, amikacin, tobramycin, and neomycin): increased risk of deafness in patients with mitochondrial mutations. January 2021 [internet publication]. https://www.gov.uk/drug-safety-update/aminoglycosides-gentamicin-amikacin-tobramycin-and-neomycin-increased-risk-of-deafness-in-patients-with-mitochondrial-mutations
Follow your local protocols on genetic testing for mitochondrial mutations. Particularly consider mitochondrial mutation screening if the patient has a maternal history of deafness or mitochondrial mutations, or is having long-term or recurrent aminoglycoside treatment. Do not delay urgent antibiotic treatment for genetic testing.[74]Medicines and Healthcare products Regulatory Agency. Aminoglycosides (gentamicin, amikacin, tobramycin, and neomycin): increased risk of deafness in patients with mitochondrial mutations. January 2021 [internet publication]. https://www.gov.uk/drug-safety-update/aminoglycosides-gentamicin-amikacin-tobramycin-and-neomycin-increased-risk-of-deafness-in-patients-with-mitochondrial-mutations
Primary options
benzylpenicillin sodium: 7.2 to 14.4 g/day intravenously given in divided doses every 4 hours for 6 weeks
or
amoxicillin: 12 g/day intravenously given in divided doses every 4 hours for 6 weeks
or
ceftriaxone: 2 g intravenously/intramuscularly every 24 hours for 6 weeks
-- AND --
gentamicin: 3 mg/kg intravenously/intramuscularly every 24 hours for 2 weeks
More gentamicinAdjust dose according to serum gentamicin level.
Secondary options
These drug options and doses relate to a patient with no comorbidities.
Primary options
benzylpenicillin sodium: 7.2 to 14.4 g/day intravenously given in divided doses every 4 hours for 6 weeks
or
amoxicillin: 12 g/day intravenously given in divided doses every 4 hours for 6 weeks
or
ceftriaxone: 2 g intravenously/intramuscularly every 24 hours for 6 weeks
-- AND --
gentamicin: 3 mg/kg intravenously/intramuscularly every 24 hours for 2 weeks
More gentamicinAdjust dose according to serum gentamicin level.
Secondary options
Drug choice, dose and interactions may be affected by the patient's comorbidities. Check your local drug formulary.
Show drug information for a patient with no comorbidities
Primary options
benzylpenicillin sodium
or
amoxicillin
or
ceftriaxone
-- AND --
gentamicin
Secondary options
vancomycin
and
gentamicin
surgery
Additional treatment recommended for SOME patients in selected patient group
Many patients require surgery. Timing of surgical intervention should be decided by a multidisciplinary endocarditis team, if available.[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com [50]Sandoe JAT, Ahmed F, Arumugam P, et al. Expert consensus recommendations for the provision of infective endocarditis services: updated guidance from the Joint British Societies. Heart. 2023 Aug 11;109(17):e2. https://www.doi.org/10.1136/heartjnl-2022-321791 http://www.ncbi.nlm.nih.gov/pubmed/36898706?tool=bestpractice.com [83]Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021 Feb 2;143(5):e35-71. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000932 http://www.ncbi.nlm.nih.gov/pubmed/33332149?tool=bestpractice.com
Indications for surgery include:[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com
Heart failure with:
Cardiogenic shock or pulmonary oedema (requires emergency surgery), or
Poor haemodynamic tolerance (requires urgent surgery)
Uncontrolled infection with:
Local complications (e.g., abscess, false aneurysm, fistula, enlarging vegetation)
Persistent positive blood cultures (despite appropriate antibiotic therapy for more than 1 week)
Resistant bacteria or fungi
Prosthetic valve endocarditis caused by Staphylococcus aureus or non-HACEK gram-negative bacilli
High risk of embolism or established embolism:
Vegetation ≥10 mm and emboli despite appropriate antibiotic therapy
Vegetation ≥10 mm and another reason for surgery (e.g., patients with significant valvular dysfunction, whether a direct result of endocarditis process or not)
Vegetation ≥10 mm and no evidence of embolus.
Temporary cardiac pacing is recommended if the patient has atrioventricular block secondary to aortic root abscess.
The aims of surgery are to remove infected tissue completely and to repair or replace the affected valves, thus restoring cardiac anatomy.
beta-lactam + rifampicin + gentamicin
Combination therapy is recommended if the patient has IE caused by Staphylococcus aureus; infection is often rapidly progressive and carries a high mortality rate.[89]John MD, Hibberd PL, Karchmer AW, et al. Staphylococcus aureus prosthetic valve endocarditis: optimal management and risk factors for death. Clin Infect Dis. 1998 Jun;26(6):1302-9. http://www.ncbi.nlm.nih.gov/pubmed/9636852?tool=bestpractice.com
If the patient has a methicillin-sensitive strain, treatment should include a beta-lactam (e.g., flucloxacillin or cefazolin) plus rifampicin for at least 6 weeks and gentamicin for 2 weeks.[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com [36]Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation. 2015 Oct 13;132(15):1435-86. http://circ.ahajournals.org/content/132/15/1435.full http://www.ncbi.nlm.nih.gov/pubmed/26373316?tool=bestpractice.com
If the patient reports a penicillin allergy, determine the timing, extent, and nature of any previous reaction.[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com
In general, if the patient has a history of type I hypersensitivity anaphylactoid reactions or severe excoriating rashes, do not give penicillins or cephalosporins (10% to 15% cross-reactivity).
If the patient has a low-risk penicillin allergy, consider giving a single dose of a penicillin or cephalosporin while monitoring the patient closely.[82]Chua KYL, Vogrin S, Bury S, et al. The penicillin allergy delabeling program: a multicenter whole-of-hospital health services intervention and comparative effectiveness study. Clin Infect Dis. 2021 Aug 2;73(3):487-96. https://academic.oup.com/cid/article/73/3/487/5879938 http://www.ncbi.nlm.nih.gov/pubmed/32756983?tool=bestpractice.com A low-risk penicillin allergy includes:[82]Chua KYL, Vogrin S, Bury S, et al. The penicillin allergy delabeling program: a multicenter whole-of-hospital health services intervention and comparative effectiveness study. Clin Infect Dis. 2021 Aug 2;73(3):487-96. https://academic.oup.com/cid/article/73/3/487/5879938 http://www.ncbi.nlm.nih.gov/pubmed/32756983?tool=bestpractice.com
Unknown reaction >10 years previously
Type A adverse drug reaction (pharmacologically predictable intolerance) where direct de-labelling was not accepted by the patient
History of an unspecified childhood rash, localised injection-site reaction (only), or maculopapular exanthem >10 years ago.
If the patient is unable to tolerate penicillin (e.g., type I hypersensitivity reaction), cefazolin plus rifampicin (for at least 6 weeks) plus gentamicin (for 2 weeks) is recommended.[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com [36]Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation. 2015 Oct 13;132(15):1435-86. http://circ.ahajournals.org/content/132/15/1435.full http://www.ncbi.nlm.nih.gov/pubmed/26373316?tool=bestpractice.com
If the patient is receiving treatment with aminoglycosides, monitor renal and liver function, and for possible ototoxicity continuously (before, during, and after treatment). Also monitor serum aminoglycoside level during treatment.[36]Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation. 2015 Oct 13;132(15):1435-86. http://circ.ahajournals.org/content/132/15/1435.full http://www.ncbi.nlm.nih.gov/pubmed/26373316?tool=bestpractice.com [74]Medicines and Healthcare products Regulatory Agency. Aminoglycosides (gentamicin, amikacin, tobramycin, and neomycin): increased risk of deafness in patients with mitochondrial mutations. January 2021 [internet publication]. https://www.gov.uk/drug-safety-update/aminoglycosides-gentamicin-amikacin-tobramycin-and-neomycin-increased-risk-of-deafness-in-patients-with-mitochondrial-mutations
The UK-based Medicines and Healthcare products Regulatory Agency has issued a drug safety alert about the increased risk of deafness associated with aminoglycoside treatment in patients with mitochondrial mutations.[74]Medicines and Healthcare products Regulatory Agency. Aminoglycosides (gentamicin, amikacin, tobramycin, and neomycin): increased risk of deafness in patients with mitochondrial mutations. January 2021 [internet publication]. https://www.gov.uk/drug-safety-update/aminoglycosides-gentamicin-amikacin-tobramycin-and-neomycin-increased-risk-of-deafness-in-patients-with-mitochondrial-mutations
Follow your local protocols on genetic testing for mitochondrial mutations. Particularly consider mitochondrial mutation screening if the patient has a maternal history of deafness or mitochondrial mutations, or is having long-term or recurrent aminoglycoside treatment. Do not delay urgent antibiotic treatment for genetic testing.[74]Medicines and Healthcare products Regulatory Agency. Aminoglycosides (gentamicin, amikacin, tobramycin, and neomycin): increased risk of deafness in patients with mitochondrial mutations. January 2021 [internet publication]. https://www.gov.uk/drug-safety-update/aminoglycosides-gentamicin-amikacin-tobramycin-and-neomycin-increased-risk-of-deafness-in-patients-with-mitochondrial-mutations
Primary options
flucloxacillin: 12 g/day intravenously given in divided doses every 4-6 hours for at least 6 weeks
or
cefazolin: 6 g/day intravenously given in divided doses every 8 hours for at least 6 weeks
-- AND --
rifampicin: 900 mg/day intravenously/orally given in divided doses every 8 hours for at least 6 weeks
More rifampicinStarting rifampicin 3-5 days later than gentamicin has been suggested by some experts.
-- AND --
gentamicin: 3 mg/kg/day intravenously/intramuscularly given in divided doses every 12-24 hours for 2 weeks
More gentamicinAdjust dose according to serum gentamicin level.
These drug options and doses relate to a patient with no comorbidities.
Primary options
flucloxacillin: 12 g/day intravenously given in divided doses every 4-6 hours for at least 6 weeks
or
cefazolin: 6 g/day intravenously given in divided doses every 8 hours for at least 6 weeks
-- AND --
rifampicin: 900 mg/day intravenously/orally given in divided doses every 8 hours for at least 6 weeks
More rifampicinStarting rifampicin 3-5 days later than gentamicin has been suggested by some experts.
-- AND --
gentamicin: 3 mg/kg/day intravenously/intramuscularly given in divided doses every 12-24 hours for 2 weeks
More gentamicinAdjust dose according to serum gentamicin level.
Drug choice, dose and interactions may be affected by the patient's comorbidities. Check your local drug formulary.
Show drug information for a patient with no comorbidities
Primary options
flucloxacillin
or
cefazolin
-- AND --
rifampicin
-- AND --
gentamicin
surgery
Additional treatment recommended for SOME patients in selected patient group
Many patients require surgery. Timing of surgical intervention should be decided by a multidisciplinary endocarditis team, if available.[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com [50]Sandoe JAT, Ahmed F, Arumugam P, et al. Expert consensus recommendations for the provision of infective endocarditis services: updated guidance from the Joint British Societies. Heart. 2023 Aug 11;109(17):e2. https://www.doi.org/10.1136/heartjnl-2022-321791 http://www.ncbi.nlm.nih.gov/pubmed/36898706?tool=bestpractice.com [83]Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021 Feb 2;143(5):e35-71. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000932 http://www.ncbi.nlm.nih.gov/pubmed/33332149?tool=bestpractice.com
Indications for surgery include:[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com
Heart failure with:
Cardiogenic shock or pulmonary oedema (requires emergency surgery), or
Poor haemodynamic tolerance (requires urgent surgery)
Uncontrolled infection with:
Local complications (e.g., abscess, false aneurysm, fistula, enlarging vegetation)
Persistent positive blood cultures (despite appropriate antibiotic therapy for more than 1 week)
Resistant bacteria or fungi
Prosthetic valve endocarditis caused by Staphylococcus aureus or non-HACEK gram-negative bacilli
High risk of embolism or established embolism:
Vegetation ≥10 mm and emboli despite appropriate antibiotic therapy
Vegetation ≥10 mm and another reason for surgery (e.g., patients with significant valvular dysfunction, whether a direct result of endocarditis process or not)
Vegetation ≥10 mm and no evidence of embolus.
Temporary cardiac pacing is recommended if the patient has atrioventricular block secondary to aortic root abscess.
The aims of surgery are to remove infected tissue completely and to repair or replace the affected valves, thus restoring cardiac anatomy.
vancomycin + rifampicin + gentamicin
Vancomycin plus rifampicin for 6 weeks is recommended if the patient has IE due to a methicillin-resistant species. Gentamicin should be used during the first 2 weeks of therapy.[36]Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation. 2015 Oct 13;132(15):1435-86. http://circ.ahajournals.org/content/132/15/1435.full http://www.ncbi.nlm.nih.gov/pubmed/26373316?tool=bestpractice.com
Methicillin-resistant species are becoming more prevalent, especially in hospitalised patients.
If the patient is receiving treatment with aminoglycosides, monitor renal and liver function, and for possible ototoxicity continuously (before, during, and after treatment). Also monitor serum aminoglycoside level during treatment.[36]Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation. 2015 Oct 13;132(15):1435-86. http://circ.ahajournals.org/content/132/15/1435.full http://www.ncbi.nlm.nih.gov/pubmed/26373316?tool=bestpractice.com [74]Medicines and Healthcare products Regulatory Agency. Aminoglycosides (gentamicin, amikacin, tobramycin, and neomycin): increased risk of deafness in patients with mitochondrial mutations. January 2021 [internet publication]. https://www.gov.uk/drug-safety-update/aminoglycosides-gentamicin-amikacin-tobramycin-and-neomycin-increased-risk-of-deafness-in-patients-with-mitochondrial-mutations
The UK-based Medicines and Healthcare products Regulatory Agency has issued a drug safety alert about the increased risk of deafness associated with aminoglycoside treatment in patients with mitochondrial mutations.[74]Medicines and Healthcare products Regulatory Agency. Aminoglycosides (gentamicin, amikacin, tobramycin, and neomycin): increased risk of deafness in patients with mitochondrial mutations. January 2021 [internet publication]. https://www.gov.uk/drug-safety-update/aminoglycosides-gentamicin-amikacin-tobramycin-and-neomycin-increased-risk-of-deafness-in-patients-with-mitochondrial-mutations
Follow your local protocols on genetic testing for mitochondrial mutations. Particularly consider mitochondrial mutation screening if the patient has a maternal history of deafness or mitochondrial mutations, or is having long-term or recurrent aminoglycoside treatment. Do not delay urgent antibiotic treatment for genetic testing.[74]Medicines and Healthcare products Regulatory Agency. Aminoglycosides (gentamicin, amikacin, tobramycin, and neomycin): increased risk of deafness in patients with mitochondrial mutations. January 2021 [internet publication]. https://www.gov.uk/drug-safety-update/aminoglycosides-gentamicin-amikacin-tobramycin-and-neomycin-increased-risk-of-deafness-in-patients-with-mitochondrial-mutations
Primary options
vancomycin: 30-60 mg/kg/day intravenously given in divided doses every 8-12 hours for at least 6 weeks
More vancomycinAdjust dose according to serum vancomycin level.
and
rifampicin: 900-1200 mg/day intravenously/orally given in divided doses every 8-12 hours for at least 6 weeks
More rifampicinStarting rifampicin 3-5 days later than gentamicin has been suggested by some experts.
and
gentamicin: 3 mg/kg/day intravenously/intramuscularly given in divided doses every 12-24 hours for 2 weeks
More gentamicinAdjust dose according to serum gentamicin level.
These drug options and doses relate to a patient with no comorbidities.
Primary options
vancomycin: 30-60 mg/kg/day intravenously given in divided doses every 8-12 hours for at least 6 weeks
More vancomycinAdjust dose according to serum vancomycin level.
and
rifampicin: 900-1200 mg/day intravenously/orally given in divided doses every 8-12 hours for at least 6 weeks
More rifampicinStarting rifampicin 3-5 days later than gentamicin has been suggested by some experts.
and
gentamicin: 3 mg/kg/day intravenously/intramuscularly given in divided doses every 12-24 hours for 2 weeks
More gentamicinAdjust dose according to serum gentamicin level.
Drug choice, dose and interactions may be affected by the patient's comorbidities. Check your local drug formulary.
Show drug information for a patient with no comorbidities
Primary options
vancomycin
and
rifampicin
and
gentamicin
surgery
Additional treatment recommended for SOME patients in selected patient group
Many patients require surgery. Timing of surgical intervention should be decided by a multidisciplinary endocarditis team, if available.[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com [50]Sandoe JAT, Ahmed F, Arumugam P, et al. Expert consensus recommendations for the provision of infective endocarditis services: updated guidance from the Joint British Societies. Heart. 2023 Aug 11;109(17):e2. https://www.doi.org/10.1136/heartjnl-2022-321791 http://www.ncbi.nlm.nih.gov/pubmed/36898706?tool=bestpractice.com [83]Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021 Feb 2;143(5):e35-71. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000932 http://www.ncbi.nlm.nih.gov/pubmed/33332149?tool=bestpractice.com
Indications for surgery include:[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com
Heart failure with:
Cardiogenic shock or pulmonary oedema (requires emergency surgery), or
Poor haemodynamic tolerance (requires urgent surgery)
Uncontrolled infection with:
Local complications (e.g., abscess, false aneurysm, fistula, enlarging vegetation)
Persistent positive blood cultures (despite appropriate antibiotic therapy for more than 1 week)
Resistant bacteria or fungi
Prosthetic valve endocarditis caused by Staphylococcus aureus or non-HACEK gram-negative bacilli
High risk of embolism or established embolism:
Vegetation ≥10 mm and emboli despite appropriate antibiotic therapy
Vegetation ≥10 mm and another reason for surgery (e.g., patients with significant valvular dysfunction, whether a direct result of endocarditis process or not)
Vegetation ≥10 mm and no evidence of embolus.
Temporary cardiac pacing is recommended if the patient has atrioventricular block secondary to aortic root abscess.
The aims of surgery are to remove infected tissue completely and to repair or replace the affected valves, thus restoring cardiac anatomy.
1st line – amoxicillin or ampicillin + ceftriaxone or gentamicin
amoxicillin or ampicillin + ceftriaxone or gentamicin
If the patient has IE due to a penicillin- or gentamicin-susceptible strain of enterococci, they should be treated with a beta-lactam (e.g., amoxicillin, ampicillin) plus ceftriaxone for 6 weeks or gentamicin for 2 weeks.
The combination of ampicillin or amoxicillin plus ceftriaxone for 6 weeks may also be used if the patient has an Enterococcus faecalis strain with high-level aminoglycoside resistance, although it is not active against Enterococcus faecium.[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com [36]Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation. 2015 Oct 13;132(15):1435-86. http://circ.ahajournals.org/content/132/15/1435.full http://www.ncbi.nlm.nih.gov/pubmed/26373316?tool=bestpractice.com
If the patient reports a penicillin allergy, determine the timing, extent, and nature of any previous reaction.[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com
In general, if the patient has a history of type I hypersensitivity anaphylactoid reactions or severe excoriating rashes, do not give penicillins or cephalosporins (10% to 15% cross-reactivity).
If the patient has a low-risk penicillin allergy, consider giving a single dose of a penicillin or cephalosporin while monitoring the patient closely.[82]Chua KYL, Vogrin S, Bury S, et al. The penicillin allergy delabeling program: a multicenter whole-of-hospital health services intervention and comparative effectiveness study. Clin Infect Dis. 2021 Aug 2;73(3):487-96. https://academic.oup.com/cid/article/73/3/487/5879938 http://www.ncbi.nlm.nih.gov/pubmed/32756983?tool=bestpractice.com A low-risk penicillin allergy includes:[82]Chua KYL, Vogrin S, Bury S, et al. The penicillin allergy delabeling program: a multicenter whole-of-hospital health services intervention and comparative effectiveness study. Clin Infect Dis. 2021 Aug 2;73(3):487-96. https://academic.oup.com/cid/article/73/3/487/5879938 http://www.ncbi.nlm.nih.gov/pubmed/32756983?tool=bestpractice.com
Unknown reaction >10 years previously
Type A adverse drug reaction (pharmacologically predictable intolerance) where direct de-labelling was not accepted by the patient
History of an unspecified childhood rash, localised injection-site reaction (only), or maculopapular exanthem >10 years ago.
If the patient is receiving treatment with aminoglycosides, monitor renal and liver function, and for possible ototoxicity continuously (before, during, and after treatment). Also monitor serum aminoglycoside level during treatment.[36]Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation. 2015 Oct 13;132(15):1435-86. http://circ.ahajournals.org/content/132/15/1435.full http://www.ncbi.nlm.nih.gov/pubmed/26373316?tool=bestpractice.com [74]Medicines and Healthcare products Regulatory Agency. Aminoglycosides (gentamicin, amikacin, tobramycin, and neomycin): increased risk of deafness in patients with mitochondrial mutations. January 2021 [internet publication]. https://www.gov.uk/drug-safety-update/aminoglycosides-gentamicin-amikacin-tobramycin-and-neomycin-increased-risk-of-deafness-in-patients-with-mitochondrial-mutations
The UK-based Medicines and Healthcare products Regulatory Agency has issued a drug safety alert about the increased risk of deafness associated with aminoglycoside treatment in patients with mitochondrial mutations.[74]Medicines and Healthcare products Regulatory Agency. Aminoglycosides (gentamicin, amikacin, tobramycin, and neomycin): increased risk of deafness in patients with mitochondrial mutations. January 2021 [internet publication]. https://www.gov.uk/drug-safety-update/aminoglycosides-gentamicin-amikacin-tobramycin-and-neomycin-increased-risk-of-deafness-in-patients-with-mitochondrial-mutations
Follow your local protocols on genetic testing for mitochondrial mutations. Particularly consider mitochondrial mutation screening if the patient has a maternal history of deafness or mitochondrial mutations, or is having long-term or recurrent aminoglycoside treatment. Do not delay urgent antibiotic treatment for genetic testing.[74]Medicines and Healthcare products Regulatory Agency. Aminoglycosides (gentamicin, amikacin, tobramycin, and neomycin): increased risk of deafness in patients with mitochondrial mutations. January 2021 [internet publication]. https://www.gov.uk/drug-safety-update/aminoglycosides-gentamicin-amikacin-tobramycin-and-neomycin-increased-risk-of-deafness-in-patients-with-mitochondrial-mutations
Primary options
amoxicillin: 200 mg/kg/day intravenously given in divided doses every 4-6 hours for 6 weeks
or
ampicillin: 12 g/day intravenously given in divided doses every 4-6 hours for 6 weeks
-- AND --
ceftriaxone: 4 g/day intravenously given in divided doses every 12 hours for 6 weeks
or
gentamicin: 3 mg/kg intravenously/intramuscularly every 24 hours for 2 weeks
More gentamicinAdjust dose according to serum gentamicin level.
These drug options and doses relate to a patient with no comorbidities.
Primary options
amoxicillin: 200 mg/kg/day intravenously given in divided doses every 4-6 hours for 6 weeks
or
ampicillin: 12 g/day intravenously given in divided doses every 4-6 hours for 6 weeks
-- AND --
ceftriaxone: 4 g/day intravenously given in divided doses every 12 hours for 6 weeks
or
gentamicin: 3 mg/kg intravenously/intramuscularly every 24 hours for 2 weeks
More gentamicinAdjust dose according to serum gentamicin level.
Drug choice, dose and interactions may be affected by the patient's comorbidities. Check your local drug formulary.
Show drug information for a patient with no comorbidities
Primary options
amoxicillin
or
ampicillin
-- AND --
ceftriaxone
or
gentamicin
surgery
Additional treatment recommended for SOME patients in selected patient group
Many patients require surgery. Timing of surgical intervention should be decided by a multidisciplinary endocarditis team, if available.[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com [50]Sandoe JAT, Ahmed F, Arumugam P, et al. Expert consensus recommendations for the provision of infective endocarditis services: updated guidance from the Joint British Societies. Heart. 2023 Aug 11;109(17):e2. https://www.doi.org/10.1136/heartjnl-2022-321791 http://www.ncbi.nlm.nih.gov/pubmed/36898706?tool=bestpractice.com [83]Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021 Feb 2;143(5):e35-71. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000932 http://www.ncbi.nlm.nih.gov/pubmed/33332149?tool=bestpractice.com
Indications for surgery include:[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com
Heart failure with:
Cardiogenic shock or pulmonary oedema (requires emergency surgery), or
Poor haemodynamic tolerance (requires urgent surgery)
Uncontrolled infection with:
Local complications (e.g., abscess, false aneurysm, fistula, enlarging vegetation)
Persistent positive blood cultures (despite appropriate antibiotic therapy for more than 1 week)
Resistant bacteria or fungi
Prosthetic valve endocarditis caused by Staphylococcus aureus or non-HACEK gram-negative bacilli
High risk of embolism or established embolism:
Vegetation ≥10 mm and emboli despite appropriate antibiotic therapy
Vegetation ≥10 mm and another reason for surgery (e.g., patients with significant valvular dysfunction, whether a direct result of endocarditis process or not)
Vegetation ≥10 mm and no evidence of embolus.
Temporary cardiac pacing is recommended if the patient has atrioventricular block secondary to aortic root abscess.
The aims of surgery are to remove infected tissue completely and to repair or replace the affected valves, thus restoring cardiac anatomy.
vancomycin + gentamicin
If the patient has IE due to Enterococcus faecalis, these strains can produce an inducible beta-lactamase, although this is rare. The patient should be treated with vancomycin for 6 weeks and gentamicin for 2 weeks.[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com
If the patient is receiving treatment with aminoglycosides, monitor renal and liver function, and for possible ototoxicity continuously (before, during, and after treatment). Also monitor serum aminoglycoside level during treatment.[36]Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation. 2015 Oct 13;132(15):1435-86. http://circ.ahajournals.org/content/132/15/1435.full http://www.ncbi.nlm.nih.gov/pubmed/26373316?tool=bestpractice.com [74]Medicines and Healthcare products Regulatory Agency. Aminoglycosides (gentamicin, amikacin, tobramycin, and neomycin): increased risk of deafness in patients with mitochondrial mutations. January 2021 [internet publication]. https://www.gov.uk/drug-safety-update/aminoglycosides-gentamicin-amikacin-tobramycin-and-neomycin-increased-risk-of-deafness-in-patients-with-mitochondrial-mutations
The UK-based Medicines and Healthcare products Regulatory Agency has issued a drug safety alert about the increased risk of deafness associated with aminoglycoside treatment in patients with mitochondrial mutations.[74]Medicines and Healthcare products Regulatory Agency. Aminoglycosides (gentamicin, amikacin, tobramycin, and neomycin): increased risk of deafness in patients with mitochondrial mutations. January 2021 [internet publication]. https://www.gov.uk/drug-safety-update/aminoglycosides-gentamicin-amikacin-tobramycin-and-neomycin-increased-risk-of-deafness-in-patients-with-mitochondrial-mutations
Follow your local protocols on genetic testing for mitochondrial mutations. Particularly consider mitochondrial mutation screening if the patient has a maternal history of deafness or mitochondrial mutations, or is having long-term or recurrent aminoglycoside treatment. Do not delay urgent antibiotic treatment for genetic testing.[74]Medicines and Healthcare products Regulatory Agency. Aminoglycosides (gentamicin, amikacin, tobramycin, and neomycin): increased risk of deafness in patients with mitochondrial mutations. January 2021 [internet publication]. https://www.gov.uk/drug-safety-update/aminoglycosides-gentamicin-amikacin-tobramycin-and-neomycin-increased-risk-of-deafness-in-patients-with-mitochondrial-mutations
Primary options
vancomycin: 30 mg/kg/day intravenously given in divided doses every 12 hours for 6 weeks
and
gentamicin: 3 mg/kg intravenously/intramuscularly every 24 hours for 2 weeks
More gentamicinAdjust dose according to serum gentamicin level.
These drug options and doses relate to a patient with no comorbidities.
Primary options
vancomycin: 30 mg/kg/day intravenously given in divided doses every 12 hours for 6 weeks
and
gentamicin: 3 mg/kg intravenously/intramuscularly every 24 hours for 2 weeks
More gentamicinAdjust dose according to serum gentamicin level.
Drug choice, dose and interactions may be affected by the patient's comorbidities. Check your local drug formulary.
Show drug information for a patient with no comorbidities
Primary options
vancomycin
and
gentamicin
surgery
Additional treatment recommended for SOME patients in selected patient group
Many patients require surgery. Timing of surgical intervention should be decided by a multidisciplinary endocarditis team, if available.[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com [50]Sandoe JAT, Ahmed F, Arumugam P, et al. Expert consensus recommendations for the provision of infective endocarditis services: updated guidance from the Joint British Societies. Heart. 2023 Aug 11;109(17):e2. https://www.doi.org/10.1136/heartjnl-2022-321791 http://www.ncbi.nlm.nih.gov/pubmed/36898706?tool=bestpractice.com [83]Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021 Feb 2;143(5):e35-71. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000932 http://www.ncbi.nlm.nih.gov/pubmed/33332149?tool=bestpractice.com
Indications for surgery include:[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com
Heart failure with:
Cardiogenic shock or pulmonary oedema (requires emergency surgery), or
Poor haemodynamic tolerance (requires urgent surgery)
Uncontrolled infection with:
Local complications (e.g., abscess, false aneurysm, fistula, enlarging vegetation)
Persistent positive blood cultures (despite appropriate antibiotic therapy for more than 1 week)
Resistant bacteria or fungi
Prosthetic valve endocarditis caused by Staphylococcus aureus or non-HACEK gram-negative bacilli
High risk of embolism or established embolism:
Vegetation ≥10 mm and emboli despite appropriate antibiotic therapy
Vegetation ≥10 mm and another reason for surgery (e.g., patients with significant valvular dysfunction, whether a direct result of endocarditis process or not)
Vegetation ≥10 mm and no evidence of embolus.
Temporary cardiac pacing is recommended if the patient has atrioventricular block secondary to aortic root abscess.
The aims of surgery are to remove infected tissue completely and to repair or replace the affected valves, thus restoring cardiac anatomy.
daptomycin + beta-lactam or fosfomycin
If the patient has IE due to vancomycin-resistant enterococci, they should be treated with daptomycin combined with a beta-lactam (e.g., ampicillin, ertapenem, ceftaroline) or fosfomycin for 6 weeks.[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com
Primary options
daptomycin: 10-12 mg/kg intravenously every 24 hours
-- AND --
ampicillin: 300 mg/kg/day intravenously given in divided doses every 4-6 hours
or
fosfomycin: 12 g/day intravenously given in divided doses every 6 hours
or
ceftaroline: 1800 mg/day intravenously given in divided doses every 8 hours
or
ertapenem: 2 g intravenously/intramuscularly every 24 hours
These drug options and doses relate to a patient with no comorbidities.
Primary options
daptomycin: 10-12 mg/kg intravenously every 24 hours
-- AND --
ampicillin: 300 mg/kg/day intravenously given in divided doses every 4-6 hours
or
fosfomycin: 12 g/day intravenously given in divided doses every 6 hours
or
ceftaroline: 1800 mg/day intravenously given in divided doses every 8 hours
or
ertapenem: 2 g intravenously/intramuscularly every 24 hours
Drug choice, dose and interactions may be affected by the patient's comorbidities. Check your local drug formulary.
Show drug information for a patient with no comorbidities
Primary options
daptomycin
-- AND --
ampicillin
or
fosfomycin
or
ceftaroline
or
ertapenem
surgery
Additional treatment recommended for SOME patients in selected patient group
Many patients require surgery. Timing of surgical intervention should be decided by a multidisciplinary endocarditis team, if available.[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com [50]Sandoe JAT, Ahmed F, Arumugam P, et al. Expert consensus recommendations for the provision of infective endocarditis services: updated guidance from the Joint British Societies. Heart. 2023 Aug 11;109(17):e2. https://www.doi.org/10.1136/heartjnl-2022-321791 http://www.ncbi.nlm.nih.gov/pubmed/36898706?tool=bestpractice.com [83]Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021 Feb 2;143(5):e35-71. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000932 http://www.ncbi.nlm.nih.gov/pubmed/33332149?tool=bestpractice.com
Indications for surgery include:[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com
Heart failure with:
Cardiogenic shock or pulmonary oedema (requires emergency surgery), or
Poor haemodynamic tolerance (requires urgent surgery)
Uncontrolled infection with:
Local complications (e.g., abscess, false aneurysm, fistula, enlarging vegetation)
Persistent positive blood cultures (despite appropriate antibiotic therapy for more than 1 week)
Resistant bacteria or fungi
Prosthetic valve endocarditis caused by Staphylococcus aureus or non-HACEK gram-negative bacilli
High risk of embolism or established embolism:
Vegetation ≥10 mm and emboli despite appropriate antibiotic therapy
Vegetation ≥10 mm and another reason for surgery (e.g., patients with significant valvular dysfunction, whether a direct result of endocarditis process or not)
Vegetation ≥10 mm and no evidence of embolus.
Temporary cardiac pacing is recommended if the patient has atrioventricular block secondary to aortic root abscess.
The aims of surgery are to remove infected tissue completely and to repair or replace the affected valves, thus restoring cardiac anatomy.
1st line – consultation with infectious disease or microbiology specialist
consultation with infectious disease or microbiology specialist
Seek advice from an infectious disease or microbiology specialist if the patient has multi-drug resistance to aminoglycosides, beta-lactams, and vancomycin; this is very difficult to manage.
surgery
Additional treatment recommended for SOME patients in selected patient group
Many patients require surgery. Timing of surgical intervention should be decided by a multidisciplinary endocarditis team, if available.[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com [50]Sandoe JAT, Ahmed F, Arumugam P, et al. Expert consensus recommendations for the provision of infective endocarditis services: updated guidance from the Joint British Societies. Heart. 2023 Aug 11;109(17):e2. https://www.doi.org/10.1136/heartjnl-2022-321791 http://www.ncbi.nlm.nih.gov/pubmed/36898706?tool=bestpractice.com [83]Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021 Feb 2;143(5):e35-71. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000932 http://www.ncbi.nlm.nih.gov/pubmed/33332149?tool=bestpractice.com
Indications for surgery include:[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com
Heart failure with:
Cardiogenic shock or pulmonary oedema (requires emergency surgery), or
Poor haemodynamic tolerance (requires urgent surgery)
Uncontrolled infection with:
Local complications (e.g., abscess, false aneurysm, fistula, enlarging vegetation)
Persistent positive blood cultures (despite appropriate antibiotic therapy for more than 1 week)
Resistant bacteria or fungi
Prosthetic valve endocarditis caused by Staphylococcus aureus or non-HACEK gram-negative bacilli
High risk of embolism or established embolism:
Vegetation ≥10 mm and emboli despite appropriate antibiotic therapy
Vegetation ≥10 mm and another reason for surgery (e.g., patients with significant valvular dysfunction, whether a direct result of endocarditis process or not)
Vegetation ≥10 mm and no evidence of embolus.
Temporary cardiac pacing is recommended if the patient has atrioventricular block secondary to aortic root abscess.
The aims of surgery are to remove infected tissue completely and to repair or replace the affected valves, thus restoring cardiac anatomy.
1st line – ceftriaxone; ampicillin + gentamicin; ciprofloxacin
ceftriaxone; ampicillin + gentamicin; ciprofloxacin
Ceftriaxone is standard treatment if the patient has Haemophilus, Aggregatibacter (formerly Actinobacillus), Cardiobacterium, Eikenella, and Kingella (HACEK) endocarditis, and should be continued for 6 weeks for prosthetic valve endocarditis.[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com
HACEK strains are also susceptible to other third-generation cephalosporins.[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com
Ampicillin should not be used as first-line therapy for treatment of HACEK endocarditis because some HACEK-group bacilli produce beta-lactamases and are increasingly ampicillin-resistant.[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com However, if they do not produce beta-lactamase, ampicillin (for 6 weeks) plus gentamicin (for 2 weeks) is an option.[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com
If the patient reports a penicillin allergy, determine the timing, extent, and nature of any previous reaction.[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com
In general, if the patient has a history of type I hypersensitivity anaphylactoid reactions or severe excoriating rashes, do not give penicillins or cephalosporins (10% to 15% cross-reactivity).
If the patient has a low-risk penicillin allergy, consider giving a single dose of a penicillin or cephalosporin while monitoring the patient closely.[82]Chua KYL, Vogrin S, Bury S, et al. The penicillin allergy delabeling program: a multicenter whole-of-hospital health services intervention and comparative effectiveness study. Clin Infect Dis. 2021 Aug 2;73(3):487-96. https://academic.oup.com/cid/article/73/3/487/5879938 http://www.ncbi.nlm.nih.gov/pubmed/32756983?tool=bestpractice.com A low-risk penicillin allergy includes:[82]Chua KYL, Vogrin S, Bury S, et al. The penicillin allergy delabeling program: a multicenter whole-of-hospital health services intervention and comparative effectiveness study. Clin Infect Dis. 2021 Aug 2;73(3):487-96. https://academic.oup.com/cid/article/73/3/487/5879938 http://www.ncbi.nlm.nih.gov/pubmed/32756983?tool=bestpractice.com
Unknown reaction >10 years previously
Type A adverse drug reaction (pharmacologically predictable intolerance) where direct de-labelling was not accepted by the patient
History of an unspecified childhood rash, localised injection-site reaction (only), or maculopapular exanthem >10 years ago.
HACEK strains are also susceptible to fluoroquinolones (e.g., ciprofloxacin), which are recommended if the patient is unable to tolerate penicillin (e.g., type I hypersensitivity reaction).
The European Medicines Agency and the UK-based Medicines and Healthcare products Regulatory Agency have issued warnings that fluoroquinolones have been associated with disabling and potentially irreversible musculoskeletal or nervous system adverse effects.[76]European Medicines Agency. Quinolone- and fluoroquinolone-containing medicinal products. March 2019 [internet publication]. https://www.ema.europa.eu/en/medicines/human/referrals/quinolone-fluoroquinolone-containing-medicinal-products [77]Medicines and Healthcare products Regulatory Agency. Fluoroquinolone antibiotics: new restrictions and precautions for use due to very rare reports of disabling and potentially long-lasting or irreversible side effects. March 2019 [internet publication]. https://www.gov.uk/drug-safety-update/fluoroquinolone-antibiotics-new-restrictions-and-precautions-for-use-due-to-very-rare-reports-of-disabling-and-potentially-long-lasting-or-irreversible-side-effects
In addition, the US Food and Drug Administration has issued warnings about the increased risk of aortic dissection, significant hypoglycaemia, and mental health adverse effects in patients taking fluoroquinolones.[78]US Food and Drug Administration. FDA drug safety communication: FDA reinforces safety information about serious low blood sugar levels and mental health side effects with fluoroquinolone antibiotics; requires label changes. October 2018 [internet publication]. https://www.fda.gov/drugs/drug-safety-and-availability/fda-reinforces-safety-information-about-serious-low-blood-sugar-levels-and-mental-health-side [79]US Food and Drug Administration. FDA drug safety communication: FDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics in certain patients. December 2018 [internet publication]. https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-increased-risk-ruptures-or-tears-aorta-blood-vessel-fluoroquinolone-antibiotics
If the patient is receiving treatment with aminoglycosides, monitor renal and liver function, and for possible ototoxicity continuously (before, during, and after treatment). Also monitor serum aminoglycoside level during treatment.[36]Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation. 2015 Oct 13;132(15):1435-86. http://circ.ahajournals.org/content/132/15/1435.full http://www.ncbi.nlm.nih.gov/pubmed/26373316?tool=bestpractice.com [74]Medicines and Healthcare products Regulatory Agency. Aminoglycosides (gentamicin, amikacin, tobramycin, and neomycin): increased risk of deafness in patients with mitochondrial mutations. January 2021 [internet publication]. https://www.gov.uk/drug-safety-update/aminoglycosides-gentamicin-amikacin-tobramycin-and-neomycin-increased-risk-of-deafness-in-patients-with-mitochondrial-mutations
The UK-based Medicines and Healthcare products Regulatory Agency has issued a drug safety alert about the increased risk of deafness associated with aminoglycoside treatment in patients with mitochondrial mutations.[74]Medicines and Healthcare products Regulatory Agency. Aminoglycosides (gentamicin, amikacin, tobramycin, and neomycin): increased risk of deafness in patients with mitochondrial mutations. January 2021 [internet publication]. https://www.gov.uk/drug-safety-update/aminoglycosides-gentamicin-amikacin-tobramycin-and-neomycin-increased-risk-of-deafness-in-patients-with-mitochondrial-mutations
Follow your local protocols on genetic testing for mitochondrial mutations. Particularly consider mitochondrial mutation screening if the patient has a maternal history of deafness or mitochondrial mutations, or is having long-term or recurrent aminoglycoside treatment. Do not delay urgent antibiotic treatment for genetic testing.[74]Medicines and Healthcare products Regulatory Agency. Aminoglycosides (gentamicin, amikacin, tobramycin, and neomycin): increased risk of deafness in patients with mitochondrial mutations. January 2021 [internet publication]. https://www.gov.uk/drug-safety-update/aminoglycosides-gentamicin-amikacin-tobramycin-and-neomycin-increased-risk-of-deafness-in-patients-with-mitochondrial-mutations
Primary options
ceftriaxone: 2 g intravenously/intramuscularly every 24 hours for 6 weeks
Secondary options
ampicillin: 12 g/day intravenously given in divided doses every 4-6 hours for 6 weeks
and
gentamicin: 3 mg/kg/day intravenously/intramuscularly given in divided doses every 8-12 hours for 2 weeks
More gentamicinAdjust dose according to serum gentamicin level.
OR
ciprofloxacin: 400 mg intravenously every 8-12 hours for 6 weeks; 750 mg orally twice daily for 4 weeks
These drug options and doses relate to a patient with no comorbidities.
Primary options
ceftriaxone: 2 g intravenously/intramuscularly every 24 hours for 6 weeks
Secondary options
ampicillin: 12 g/day intravenously given in divided doses every 4-6 hours for 6 weeks
and
gentamicin: 3 mg/kg/day intravenously/intramuscularly given in divided doses every 8-12 hours for 2 weeks
More gentamicinAdjust dose according to serum gentamicin level.
OR
ciprofloxacin: 400 mg intravenously every 8-12 hours for 6 weeks; 750 mg orally twice daily for 4 weeks
Drug choice, dose and interactions may be affected by the patient's comorbidities. Check your local drug formulary.
Show drug information for a patient with no comorbidities
Primary options
ceftriaxone
Secondary options
ampicillin
and
gentamicin
OR
ciprofloxacin
surgery
Additional treatment recommended for SOME patients in selected patient group
Many patients require surgery. Timing of surgical intervention should be decided by a multidisciplinary endocarditis team, if available.[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com [50]Sandoe JAT, Ahmed F, Arumugam P, et al. Expert consensus recommendations for the provision of infective endocarditis services: updated guidance from the Joint British Societies. Heart. 2023 Aug 11;109(17):e2. https://www.doi.org/10.1136/heartjnl-2022-321791 http://www.ncbi.nlm.nih.gov/pubmed/36898706?tool=bestpractice.com [83]Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021 Feb 2;143(5):e35-71. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000932 http://www.ncbi.nlm.nih.gov/pubmed/33332149?tool=bestpractice.com
Indications for surgery include:[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com
Heart failure with:
Cardiogenic shock or pulmonary oedema (requires emergency surgery), or
Poor haemodynamic tolerance (requires urgent surgery)
Uncontrolled infection with:
Local complications (e.g., abscess, false aneurysm, fistula, enlarging vegetation)
Persistent positive blood cultures (despite appropriate antibiotic therapy for more than 1 week)
Resistant bacteria or fungi
Prosthetic valve endocarditis caused by Staphylococcus aureus or non-HACEK gram-negative bacilli
High risk of embolism or established embolism:
Vegetation ≥10 mm and emboli despite appropriate antibiotic therapy
Vegetation ≥10 mm and another reason for surgery (e.g., patients with significant valvular dysfunction, whether a direct result of endocarditis process or not)
Vegetation ≥10 mm and no evidence of embolus.
Temporary cardiac pacing is recommended if the patient has atrioventricular block secondary to aortic root abscess.
The aims of surgery are to remove infected tissue completely and to repair or replace the affected valves, thus restoring cardiac anatomy.
1st line – consultation with infectious disease or microbiology specialist
consultation with infectious disease or microbiology specialist
Seek advice from an infectious disease or microbiology specialist if the patient has IE due to a culture-negative (non-HACEK) micro-organism.
Various mechanisms of antibiotic resistance are found in non-HACEK organisms.
A variety of organisms are implicated: Chlamydia species, Coxiella species, Bartonella species, Brucella species, and Legionella species.
surgery
Additional treatment recommended for SOME patients in selected patient group
Many patients require surgery. Timing of surgical intervention should be decided by a multidisciplinary endocarditis team, if available.[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com [50]Sandoe JAT, Ahmed F, Arumugam P, et al. Expert consensus recommendations for the provision of infective endocarditis services: updated guidance from the Joint British Societies. Heart. 2023 Aug 11;109(17):e2. https://www.doi.org/10.1136/heartjnl-2022-321791 http://www.ncbi.nlm.nih.gov/pubmed/36898706?tool=bestpractice.com [83]Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021 Feb 2;143(5):e35-71. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000932 http://www.ncbi.nlm.nih.gov/pubmed/33332149?tool=bestpractice.com
Indications for surgery include:[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com
Heart failure with:
Cardiogenic shock or pulmonary oedema (requires emergency surgery), or
Poor haemodynamic tolerance (requires urgent surgery)
Uncontrolled infection with:
Local complications (e.g., abscess, false aneurysm, fistula, enlarging vegetation)
Persistent positive blood cultures (despite appropriate antibiotic therapy for more than 1 week)
Resistant bacteria or fungi
Prosthetic valve endocarditis caused by Staphylococcus aureus or non-HACEK gram-negative bacilli
High risk of embolism or established embolism:
Vegetation ≥10 mm and emboli despite appropriate antibiotic therapy
Vegetation ≥10 mm and another reason for surgery (e.g., patients with significant valvular dysfunction, whether a direct result of endocarditis process or not)
Vegetation ≥10 mm and no evidence of embolus.
Temporary cardiac pacing is recommended if the patient has atrioventricular block secondary to aortic root abscess.
The aims of surgery are to remove infected tissue completely and to repair or replace the affected valves, thus restoring cardiac anatomy.
1st line – consultation with infectious disease or microbiology specialist
consultation with infectious disease or microbiology specialist
Seek early advice from an infectious disease or microbiology specialist if the patient has fungal IE.[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com Mortality is very high (>50%).[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com
Be aware that fungal infections most frequently affect patients with prosthetic valves and those who are immunocompromised.
Patients who use intravenous drugs are also at increased risk of fungal IE.
The most common causative agents are Candida and Aspergillus.
Treatment includes valve replacement and antifungal therapy.[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com [80]Ellis ME, Al-Abdely H, Sandridge A, et al. Fungal endocarditis: evidence in the world literature, 1965-1995. Clin Infect Dis. 2001 Jan;32(1):50-62. http://cid.oxfordjournals.org/content/32/1/50.long http://www.ncbi.nlm.nih.gov/pubmed/11118386?tool=bestpractice.com
Valve replacement surgery needs be performed as soon as possible in prosthetic valve Candida endocarditis.[90]Cornely OA, Bassetti M, Calandra T, et al; ESCMID Fungal Infection Study Group. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect. 2012 Dec;18 (Suppl 7):19-37. http://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(14)60765-5/fulltext http://www.ncbi.nlm.nih.gov/pubmed/23137135?tool=bestpractice.com
at high risk of infective endocarditis
advice ± antibiotic prophylaxis
Guidelines differ in their recommendations for antibiotic prophylaxis; check your local protocol. Decisions about antibiotic prophylaxis should only be made after careful evaluation of the individual patient’s circumstances, following discussion with the patient, taking into account the patient’s values and preferences, and using your clinical judgement.
The European Society of Cardiology (ESC) recommends that antibiotic prophylaxis should only be considered if the patient is at highest risk of IE and undergoing a dental procedure that requires manipulation of the gingival or periapical region of the teeth or perforation of the oral mucosa. The ESC considers a patient to be at highest risk of IE if they have:[7]Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023 Oct 14;44(39):3948-4042. https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=false http://www.ncbi.nlm.nih.gov/pubmed/37622656?tool=bestpractice.com
A prosthetic valve, including a transcatheter valve or a valve in which any prosthetic material was used for valve repair
A history of a previous episode of IE
Untreated cyanotic congenital heart disease or congenital heart disease that has been repaired with a prosthetic material (including valved conduits or systemic-to-pulmonary shunts)
A ventricular assist device.
In the UK, the National Institute for Health and Care Excellence (NICE) recommends that an at-risk patient undergoing interventional procedures should not be given antibiotic prophylaxis against IE routinely. However, NICE emphasises that antibiotic therapy is still necessary to treat active or potential infections.[17]National Institute for Health and Care Excellence. Prophylaxis against infective endocarditis: antimicrobial prophylaxis against infective endocarditis in adults and children undergoing interventional procedures. July 2016 [internet publication]. https://www.nice.org.uk/guidance/cg64 NICE considers a patient to be at risk if they have:[17]National Institute for Health and Care Excellence. Prophylaxis against infective endocarditis: antimicrobial prophylaxis against infective endocarditis in adults and children undergoing interventional procedures. July 2016 [internet publication]. https://www.nice.org.uk/guidance/cg64
Acquired valvular heart disease with stenosis or regurgitation
Hypertrophic cardiomyopathy
Previous IE
Structural congenital heart disease, including surgically corrected or palliated structural conditions, but excluding isolated atrial septal defect, fully repaired ventricular septal defect, fully repaired patent ductus arteriosus, and closure devices that are judged to be endothelialised
Valve replacement.
NICE recommends giving clear information about prevention to any patient at risk of IE, which should include:[17]National Institute for Health and Care Excellence. Prophylaxis against infective endocarditis: antimicrobial prophylaxis against infective endocarditis in adults and children undergoing interventional procedures. July 2016 [internet publication]. https://www.nice.org.uk/guidance/cg64
The benefits and risks of antibiotic prophylaxis, and an explanation of why antibiotic prophylaxis is no longer routinely recommended
The importance of maintaining good oral health
Symptoms that may indicate IE and when to seek expert advice
The risks of undergoing invasive procedures, including non-medical procedures such as body piercing or tattooing.
The recommendations from the ESC and NICE may not be universally accepted in other countries.
The most common cause of infective endocarditis following dental, oral, respiratory tract, or oesophageal procedures is Streptococcus viridans (alpha-haemolytic streptococci). Therefore, antibiotics (if they are to be given for prophylaxis) are directed toward this organism, and administered as a single dose 30 to 60 minutes before the procedure.
Base your choice of antibiotic on your local hospital protocols.
The evidence for antibiotic prophylaxis preventing infection following dental procedures and instrumentation of the respiratory, genitourinary, or gastrointestinal tract is weak. Conflicting data suggest that a reduction in bacteraemia may not result in a lower incidence of infective endocarditis in low-risk individuals.[20]Cahill TJ, Harrison JL, Jewell P, et al. Antibiotic prophylaxis for infective endocarditis: a systematic review and meta-analysis. Heart. 2017 Jun;103(12):937-44. http://www.ncbi.nlm.nih.gov/pubmed/28213367?tool=bestpractice.com The risk of bacteraemia resulting from interventions such as dental procedures and instrumentation of the respiratory, genitourinary, or gastrointestinal tract is significantly smaller than from usual life-time activities such as toothbrushing or chewing.[21]Lockhart PB, Brennan MT, Sasser HC, et al. Bacteremia associated with toothbrushing and dental extraction. Circulation. 2008 Jun 17;117(24):3118-25. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2746717 http://www.ncbi.nlm.nih.gov/pubmed/18541739?tool=bestpractice.com Data have indicated that, even if treatment with prophylactic antibiotics were 100% effective, only a small number of cases would be prevented.
Primary options
amoxicillin: 2 g orally as a single dose 30-60 minutes before procedure
OR
ampicillin: 2 g intravenously/intramuscularly as a single dose 30-60 minutes before procedure
Secondary options
cefalexin: 2 g orally as a single dose 30-60 minutes before procedure
OR
ceftriaxone: 1 g intravenously/intramuscularly as a single dose 30-60 minutes before procedure
OR
cefazolin: 1 g intravenously/intramuscularly as a single dose 30-60 minutes before procedure
OR
azithromycin: 500 mg orally as a single dose 30-60 minutes before procedure
OR
clarithromycin: 500 mg orally as a single dose 30-60 minutes before procedure
OR
doxycycline: 100 mg orally as a single dose 30-60 minutes before procedure
Choose a patient group to see our recommendations
Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups. See disclaimer
Use of this content is subject to our disclaimer